affidavit of david e. smith, m.d., fasam, faact...

i

STATE OF CALIFORNIA

COUNTY OF SAN FRANCISCO

AFFIDAVIT OF DAVID E. SMITH, M.D., FASAM, FAACT PERSONALLY APPEARED before the undersigned officer duly authorized to

administer oaths in this State, DAVID E. SMITH, M.D., who, after first being duly

sworn, states as follows:

My name is DAVID E. SMITH, M.D. I am a medical doctor, licensed to

practice medicine in the State of California. I practice in the specialty of addiction

medicine, in which I am board-certified. A true and correct copy of my curriculum vitae

is attached hereto as Exhibit A.

I make this affidavit based upon my own personal knowledge and belief. I am

over the age of eighteen years, and I suffer from no disability which would render me

incompetent to make this affidavit.

Based upon my education, training and experience, I am familiar with the degree

of care and skill ordinarily exercised by physicians generally, and those specializing in

the specialty of addiction medicine, to include those serving in the capacity of medical

directors or clinical directors of licensed drug and alcohol rehabilitation facilities ("the

standard of care"), with regard to both the evaluation and treatment of patients who are

admitted to drug and alcohol rehabilitation facilities for treatment for addictions and the

discharge of the patient care responsibilities customarily associated with serving as

1.

2.

3.

PLAINTIFF'S EXHIBIT

A

)

medical directors or clinical directors of such facilities. Specifically, I am familiar with

the standard of care ordinarily exercised by medical doctors generally in the care and

treatment of a patient such as Patrick W. Desmond, as his circumstances and conditions

are discussed herein.

. 4.

In connection with giving this affidavit, I have reviewed the following materials:

Brevard County Drug Court Records; Patrick W. Desmond's Death Certificate; DeKalb

County Fire & Rescue Report; DeKalb County Medical Examiner's Report; Georgia

Department of Human Resources materials; DHR Applications for License; Narconon

Brochure; Narconon Discharge Summary; Narconon Family & Friends Orientation

materials; Narconon Medical Records; Narconon Outpatient Protocol; Narconon

Program Description; Northside Hospital Records; and, Peachford Hospital Records.

5.

Additionally, I have been provided with a copy of the Complaint, which I

understand is to be filed in this case, and have been asked to assume the following facts,

which are consistent with my review of the information identified in Paragraph 3, above:

• The Brevard County Drug Court required that Patrick W. Desmond be enrolled

in an in-patient, residential facility where he would be closely supervised at all

times.

• Narconon made representations to Patrick's parents and the manager of the

Brevard County Drug Court that Narconon was a residential facility and met the

Drug Court 's requirements.

However, Narconon was never licensed to operate any category of residential

program.

Instead, Narconon was licensed to operate an outpatient facility with a sub-unit

or branch ambulatory detoxification services program at a separate location,

which were by law specifically limited to the provision of services in non

residential settings. .

Despite being licensed to provide services only in non-residential settings,

Narconon maintained operated off-site housing programs in several apartment

complexes, including a program for male patients at One Sovereign Place,

located at 4883 Roswell Road, Atlanta/Sandy Springs, Georgia.

Specifically, an agent for and on behalf of Narconon leased apartments at One

Sovereign Place for the specific purpose of housing Narconon's patients; and

likewise provided monitoring services to the patients while they were physically

present at the One Sovereign Place.

Dr. Robbins was the medical director of Narconon and had responsibilities for

assessing prospective clients for medical, behavioral and/or emotional problems,

determining the needed level of structured treatment and therapeutical activities,

establishing procedures for a system of 24-hour, on call medical coverage to

include delivery of emergency medical services, providing medical management

services to include approving protocols and procedures, being actively involved

in a quality assurance program to evaluate the appropriateness of services

provided to patients, and otherwise overseeing Narconon's operations.

3

Patrick Desmond first arrived at Narconon on September 24, 2007 and was

assessed by Dr. Robbins the same day. He was enrolled as a paying patient in

the Narconon program, to include the illegal drug and alcohol rehabilitation

housing program at the One Sovereign Place apartment complex, for

approximately four and one-half months, and successfully completed and was

"graduated''' from Narconon's program on or about February 12, 2008, several

weeks prior of the completion of the Drug Court 's mandated six month treatment

period. He then stayed on as a staff member for the housing and sauna programs

for the remainder of the six month treatment period.

Following his initial participation in Narconon's program, Patrick returned to his

family's home in Florida, but failed a required alcohol test on May 20, 2008.

This incident led to him being compelled by the Drug Court to return to

Narconon's facility.

Patrick returned to Narconon on May 23, 2008 and was reassessed by Defendant

Dr. Robbins on June 3, 2008.

On the evening of June 10, 2008, Patrick was drinking beer and vodka with

Narconon employees and staff members in a staff member 's apartment at One

Sovereign Place.

After becoming highly intoxicated with Narconon's employees and staff

members, Patrick left the illegal housing program's premises with two former

patients of Narconon who had announced their intention to attempt to buy heroin.

The Narconon employees and staff members were aware that Patrick intended to

leave these individuals for the purpose of attempting to buy heroin, but failed to

)

intervene to prevent him from doing so. The Narconon employees and staff

members likewise failed to make any timely report to their superiors or law-

enforcement that Patrick had left the premises.

• No security and no reasonable or adequate supervision or monitoring to ensure

that neither Patrick nor any other drug or alcohol-dependant patient would be

allowed to freely leave the housing program premises at their own discretion for

the purpose of engaging in on-going abuse of drugs and alcohol was provided by

or on behalf of Narconon for the benefit and safety of the patients.

• No security and no reasonable or adequate supervision or monitoring to ensure

that Narconon's patients would not engage in on-going abuse of drugs and

alcohol at the housing program premises was provided by or on behalf of

Narconon for the benefit and safety of the patients.

• Shortly before 2:00 A.M. on the morning of June 11, 2008, emergency medical

personnel responded to a 911 call placed by two former patients of Narconon

from a vehicle stopped on the shoulder of 1-285 in DeKalb County. When

emergency personnel arrived on the scene, they found Patrick in

cardiopulmonary arrest with no blood pressure or pulse. He was taken to

Northside Hospital Emergency Department where the emergency physician

diagnosed Patrick with cardiopulmonary arrest secondary to heroin overdose.

• Patrick was pronounced dead at 5:15 P.M. on June 11, 2008.

6.

Based upon the aforementioned documents and assumed facts, and upon my

education, training and experience, it is my opinion that Lisa C. Robbins, M.D., in her

5

)

care and treatment of Patrick W. Desmond failed to exercise the degree of care and skill

ordinarily exercised by members of the medical profession generally under the same or

similar circumstances. Specifically, Dr. Robbins, as the medical director of Narconon of

Georgia, failed to exercise authority and responsibility for the oversight and safety of the

patients at Narconon. At minimum, the standard of care required that a patient such as

Patrick be provided with reasonable and adequate supervision by properly qualified and

trained staff during their drug and alcohol rehabilitation treatment. Although Patrick was

not enrolled in a licensed residential facility, as required by the Brevard County Drug

Court, he was nevertheless placed in a housing program setting. Under such

circumstances, it was medically necessary that reasonable or adequate supervision or

monitoring be provided to ensure that Patrick and other drug or alcohol-dependant

patients would not be allowed to freely leave the housing program premises at their own

discretion for the purpose of engaging in on-going abuse of drugs and alcohol and

similarly would not be allowed to engage in on-going abuse of drugs and alcohol at the

housing program premises. As Narconon's medical director, Dr. Robbins had

responsibility for the failure to provide reasonable or adequate supervision or monitoring

in the unlicensed housing program setting.

7.

It is further my opinion that the said departures from the standard of care, to a

reasonable degree of medical certainty, caused or contributed to the death of Patrick W.

Desmond.

8.

6

DAVID E . SMITH, MD, FASAM, FAACT

Specialty Areas: Addiction Medicine

Clinical Toxicology License: Medical (California Board of Medical Quality Assurance) Certification: Addiction Medicine (American Society of Addiction Medicine)

Addiction Medicine (American Board of Addiction Medicine)

Address:

Telephone: Facsimile: E-Mail:

David E. Smith, M.D. and Associates 856 Stanyan Street San Francisco, CA 94117 (415)933-8759 (415) 933-8674 [email protected]

Short Biography for Introduction • Diplomate, American Board of Addiction Medicine • Chair, Adolescent Addiction Treatment, Newport Academy, Corona Del Mar, California • Medical Director, Center Point, San Rafael, California • Adjunct Professor, University of California, San Francisco • Former Medical Director, California State Department of Alcohol and Drug Programs • Fellow and Past President, American Society of Addiction Medicine • Fellow, American Academy of Clinical Toxicologists • Founder, Haight Ashbury Free Medical Clinic, San Francisco, California

PLAINTIFF'S EXHIBIT

1 1

David E. Smith, M.D. Page 2

I. Current Medical Practice • Chair, Adolescent Addiction Treatment, Newport Academy, Corona Del Mar, California 2008-Present • Medical Director, Center Point, Inc., San Rafael, California 1993-Present • Medical Review Officer - PG&E, San Francisco, California 1990-Present • Adjunct Professor, University of California San Francisco 2000-Present • Diplomate, American Board of Addiction Medicine 2009-Present • Fellow, American Society of Addiction Medicine 1997-Present • Fellow, American Academy of Clinical Toxicology 1987-Present

II. Education East Bakersfield High School Bakersfield College, A.A. University of California, Berkeley, B.A., Zoology University of California, San Francisco, M.S., Pharmacology University of California, San Francisco, M.D., Medicine San Francisco General Hospital, Internship University of California, San Francisco, Post-Doctoral Fellowship, Pharmacology and Toxicology Institute for the Advanced Study of Human Sexuality, Ph.D. coursework

1964

1956 1958 1960

1964 1965

1965-1967 1979-1984

H. Current Medical Practice • Chair, Adolescent Addiction Treatment, Newport Academy, Corona Del Mar, California 2008-Present • Medical Director, Center Point, Inc., San Rafael, California 1993-Present • Medical Review Officer - PG&E, San Francisco, California 1990-Present • Adjunct Professor, University of California San Francisco 2000-Present • Diplomate, American Board of Addiction Medicine 2009-Present • Fellow, American Society of Addiction Medicine 1997-Present


• Fellow, American Academy of Clinical Toxicology 1987-Present

III. Past Medical Practice Executive Medical Director, Prometa Center, San Francisco Chief of Addiction Medicine, Bayside Marin, Tiburon, California Medical Director, Haight Ashbury Free Clinics Research Director, MPI Treatment Services, Summit Medical Center,

Oakland, California Medical Director, California Collaborative Center for Substance Abuse Policy Research, University of California, San Francisco Medical Director, California State Department of Alcohol and Drug Programs Doping Control Officer, Winter Olympics, Salt Lake City Medical Staff, Fresno Community Hospital and Medical Center, Community Hospitals of Central California, Fresno, California Medical Review Officer - University of California, Berkeley Medical Director, Forest Farms Community, Adolescent Drug Treatment Program, Forest Knolls, California Consultant on Drug Abuse, Gladman Memorial Psychiatric Hospital, Oakland, California Consultant on Drug Abuse, Marin Alternative Community Therapy, San Rafael, California Member, U.S. Olympic Team, Doping Control Section San Francisco Psychiatric Hospital Courtesy Staff Physician, Presbyterian Alcoholic Clinic Physician, Contra Costa Alcoholic Clinic Director, Alcohol & Drug Abuse Screening Unit, San Francisco General Hospital

2006-2008 2006-2008 1967-2006 1984-2003 1998-2007 1998-2006 2002 1993-1995 1996-2006 1983-1994 1981-1986 1978-1984 1984 1973-1977 1965-1966 1965-1968 1965-1972

IV. Teaching Activities 1. Adjunct Professor, University of California, San Francisco 2. Visiting Research Professor, University of California, San Francisco 3. Associate Clinical Professor of Occupational Health and Clinical Toxicology,

Department of Occupational Health, University of California, San Francisco 4. Associate Clinical Professor of Clinical Toxicology, University of California,

San Francisco Lecturer in Criminology, University of California, Berkeley Co-Director, National Training Center for Drug Education, San Francisco, California Preceptor, Community Medicine Preceptorship Program, University of California, San Diego Faculty Member, National College of Juvenile Justice, University of Nevada, Reno, Nevada

9. Honorary Lecturer, Department of Medicine, Addiction Research Foundation Clinical Institute, Toronto, California

10. Visiting Clinical Professor of Behavioral Pharmacology, University of Nevada Medical School Lecturer on Substance Abuse, UC Berkeley-UC San Francisco Joint Medical School Program Guest Lecturer on Substance Use Disorders Assessment & Management of Common Psychiatric Symptoms Course, UCSF Department of Community Health Systems

11 12

2000-present 1998-2000 1986-Present 1967- Present 1968- 1969 1970 1972-1973 1971-1976 1975-1990 1975-Present 1980-Present

November 1999

1 David E. Smith, M.D.

Page 4

V. Consultancies 1. Consultant, Drug Abuse Division of Alcoholism, California Department of

Public Health 2. Consultant, Drug Abuse, Veteran's Administration Hospital 3. Consultant, Student Association for the Study of Hallucinogens 4. Consultant, National Commission on Venereal Disease 5. Consultant, President's Special Action Office on Drug Abuse Prevention 6. Consultant, Committee on Dangerous Drugs, California Medical Association 7. Consultant on Drug Abuse, United States Air Force 8. Consultant on Drug Abuse, National Association of Drag Abuse 9. Consultant on Drug Abuse, SAODAP 10. Consultant on Drug Abuse, NIMH 11. Consultant to NIMH - National Clearinghouse on Drug Abuse Information 12. Consultant to NTMH - NARB Drug Treatment Program 13. Consultant to Committee on Alcoholism and Drug Dependence,

1973 House of Delegates 14. Advisory Council, Department of Health, Education & Welfare 15. Advisory Board to PHARMCHEM Research Foundation 16. Consultant, Stanford Research Institute on Drug Abuse 17. Consultant, Alcohol and Drug Abuse, AMA Council on Scientific Affairs 18. Advisory Committee, San Francisco Health Department, Sexual Trauma Center 19. Advisory Council on Narcotics and Drug Abuse, Sacramento, California 20. Advisory Committee on Controlled Substances, Food and Drug Administration,

Washington, DC 21. Consultant, Menninger Clinic, Topeka, Kansas 22. Consultant, San Francisco General Hospital, Department of Psychiatry 23. Consultant, Committee on Alcoholism and Other Drug Dependencies,

California Medical Association 24. Consultant, American Medical Association Diagnostic and Therapeutic

Technology Assessment 25. Consultant and Member Advisory Board, Marin A.C.T. 26. Alternate Delegate to the American Medical Association representing

the American Medical Society on Alcoholism and Other Drug Dependencies 27. American Psychiatric Association: Consultant to Substance Abuse Section,

Work Group to revise DSM-III 28. Johnson Institute: Faculty Training Position 28. Alcohol, Tobacco & Other Drugs Advanced Practice Nursing Subspecialty Program:

Advisory Committee 30. United States Olympic Committee National Anti-Doping Program Review 31. International Society of Addiction Medicine (ISAM)

Chairman, Health Economics Committee

1966-1968 1968-Present 1968-1980 1971-1972 1971- 1973 1970-1973 1972- 1973 1972-1984 1972-1973 1972-1973 1972-1974 1972-1974 1973 1973 1975-1984 1975-1976 1977 1977 1979-1980 1978-1983 1983-1995 1966-Present 1978-1990 1982-1985 1982-1985 1989-Present 1990 1990 1998 1998 1999- Present

VI. Coordinating Agencies 1. Founder, Former President and Former Coordinating Committee Member,

National Free Clinic Council 1968-1972

VII. Memberships 1. Member, U.S. Office of Education, Drug Education Project and

Assistant Director, West Coast Regional Training Center 1970

\


2. 3. 4.

6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 21. 22. 24. 25. 26. 27. 28. 29. 30. 31.

Member, Advisory Board of Contemporary Drug Problems Member, Governor's Task Force on Veteran Drug Addicts Member, San Francisco Association for Mental Health Professional Advisory Committee Member, San Francisco Medical Society for Alcoholism and Dangerous Drugs Committee Ad Hoc Committee - City College Student Health Services Member, Scientific Review Boards Methadone Maintenance Program Member, Pan American Medical Association Member, Scientific Advisory Committee on Drugs, National Research Council Member, PAMA Section on Drug Abuse and Narcotic Addiction Member, PAMA Section on Forensic Medicine Associate Member, World Medical Association Member, National Association State Drug Coordinator, Drug Abuse Prevention Task Force Board Member, Westside Community Mental Health Center Member, Royal Society of Medicine, London, England Member, Conference Organizing Committee First Annual National Drug Abuse Conference, Chicago, Illinois Board of Directors Community Management Center Member, Clinical Review Board, National Institute on Drug Abuse Co-Chairman, National Free Clinic Council, National Free Clinic Physicians Caucus Member, Board of Directors, Haight Ashbury Switchboard Member, American College of Emergency Physicians Member, Advisory Board of the National Drug Abuse Center for Training and Resource Development Member, Professional Advisory Board, "The Door: A Center of Alternatives," New York, New York Member, San Francisco Heart Association Member, Northwestern Medical Association, Inc. Member, Board of Advisors, Awareness House, Oakland, California Member, California PCP Training Project Technical Advisory Group Member, Physicians for Prevention, White House Office on Drug Control Policy Member, National Council on Alcoholism and Drug Dependence, Inc. Member, Prescription Drug Research Center, Chicago, Illinois Member, Independent Advisory Committee on Prescription Stimulant Abuse

1971 1971 1970-1973 1970- 1985 1972 1972 1972-1995 1971- 1972 1972- 1995 1972-1995 1972- 1995 1982-1995 1973 1973 1974 1973 1973- Present 1974 1974- 1975

1972-1995 1975- 1995 1974-1985 1976- 1977 1974-1990 1977 1978-1979

1995-Present 1995-Present 2004 2007-Present

VII. Societies 1. Member, San Francisco Medical Society Drug Abuse Committee,

Physician's Well Being Committee 2. San Francisco Medical Society Local Health Affairs Committee 3. San Francisco Medical Society Editorial Board 4. Member, California Medical Association Drug Abuse Committee,

Prescription Drug Committee 5. Member, American Medical Association Drug Abuse Committee 6. Member, California Society of Addiction Medicine 7. Member, American Society of Addiction Medicine Board of Directors,

Special Status Committee, Nomenclature Committee 8. Member, Board of Medical Quality Assurance, Diversion Liaison Committee 9. Member, Phi Beta Kappa 10. Member, Sigma Xi 11. American Public Health Association (Mental Health Section)

1965-Present 1997-Present 1999-Present 1965-Present 1965-Present 1972-Present 1972-Present 1982-1984 1960-Present 1960-Present 1968-Present

) )


12. Charter Member, American Academy of Clinical Toxicology 13. Charter Member and Chairman, Editorial Committee, California Society for the

Treatment of Alcoholism and other Drug Dependencies 14. Member, San Francisco Society Board of Medical Quality Assurance Committee 15. Member, Western Pharmacology Society 16. Member, Committee on the Well Being of Physicians,

California Medical Association 17. Chairman, Well Being Committee, American Society of Addiction Medicine 18. Founding Board of Directors, International Society of Addiction Medicine (ISAM) 19. Chairman, Pain and Addiction Committee, International Society of Addiction

Medicine

1968-Present 1973-Present

1979 1970-Present 1997-Present 1999 1999 2002

IX. Training Activities 1. Chairperson, National Drug Abuse Conference, San Francisco 2. National Institute on Drug Abuse Training Advisory Committee 3. Director, Amphetamine Evaluation and Physician Training Project 4. Director, PCP Research and Training Project 5. Co-Director, Impaired Health Professional Research and Training 6. Director, Benzodiazepine Research & Physician Training Project 7. Co-Director, Drug Abuse and Sexual Dysfunction Research and

Physician Training Project 8. Medical Director, Haight Ashbury Training and Education Project

1977 1978-1990 1977- 1979 1978- 1980 1980-1990 1980-1985 1979- 1985 1980- 1995

X. Political and Governmental Positions/Activities 1. Member, Task Force on Domestic Affairs at the Advisory Council of the Elected

Officials to the Democratic National Committee: A Study Group in Drug Abuse and Alcoholism

2. Co-Chairman, Northern California Physicians for McGovem for President 3. Chairman, Northern California Physicians for Carter for President 4. Health Advisor to President Jimmy Carter 5. Alcoholism and Drug Abuse Sub-Committee for the Democratic National Platform 6. Member, Governor's Advisory Panel on Narcotics and Drug Abuse 7. Consultant, FDA Controlled Substances Advisory Committee 8. Consultant, National Institute of Drug Abuse 9. Member, Committee on Impaired Health Professionals, California Society

for the Treatment of Alcoholism and Other Drug Dependencies 10. Physician's Representative on the California State Controlled Substance

Prescription Drug Advisory

1971 1972 1975-1976 1976 1976 1977 1978-1983

1976-1984 1980 1993

XI. Honors 1. Borden Research Award 1964 2. Research Award 1966 3. California Junior College Alumnus of the Year 1969 4. Chancellor's Award for Community Service, University of California,

San Francisco 1974 5. 16th Annual San Francisco Examiner "Ten Most Distinguished" Award 6. American Medical Association Physician's Recognition Award in Continuing Education 1978 7. Martin Luther King Humanitarian Award, Glide Methodist Church,

San Francisco, California 1980

1974


8. Drug Abuse Treatment Award, California Association State Drug Abuse Coordinators 1983 9. Drug Abuse Treatment Award, National Association, State Alcohol and Drug Abuse

Coordinators 1984 10. Career Achievement Award, National Association of State Alcohol and Drug Abuse

Directors (NASADAD) and National Prevention Network 1994 11. University of California Medal of Honor Recipient 1995 12. Community Works Award, State of California Drug Policy Office 1996 13. The Best Doctors in America: Pacific Region 1996-1997 14. California Medicine Magazine; named one of "California's 100 Most

Interesting and Influential Health Care Leaders" 1997 15. California Association of Alcoholism and Drug Abuse Counselors

(CAADAC) Council of Fellows 1998 16. Haight Ashbury Free Clinics, Lifetime Achievement Award 1998 17. Geri Taylor Memorial Award, Northern California Psychiatric Society 1998 18. Talbott Recovery Campus Award 1999 19. Governor's Older Worker and Exemplary Employer Recognition Award 2002

XII. Editorial Positions 1. Founder and Executive Editor, Journal of Psychoactive Drugs (formerly known as

Journal of Psychedelic Drugs) 2. Member, Editorial Board, The Journal, the official publication of the Toronto

Addiction Research Institute 3. Member, Editorial Board, Clinical Toxicology 4. Co-Editor, Addictions Alert Newsletter 5. Contemporary Drug Problems: A Law Quarterly 6. Journal ofAmerican College of Emergency Physicians 7. Editorial Board, Drug Abuse and Drug Education 8. Editorial Board, Clinical Toxicology 9. Editorial Advisory Board^4merican Journal of Drug and Alcohol Abuse 10. Advisory Board, The Center for the Study of Non-Medical Drug Use 11. Advisory Board, Women In Crisis, Inc., New York 12. Editorial Advisory Board, Journal of the American Medical Association 13. Medical Editor, AlcoholMD.com 14. Editorial Board, Journal of Addiction Medicine

1967-Present 1974- 1993 1975- 2007 1987-2005

1973 1976-Present 1981-2005 1984-2006 2000-Present 2002-Present

XIII. Research Projects 1. Assistant Principal Investigator, C.R.C. Dug Abuse Social Rehabilitation and Demonstration

Project. Department of Health, Education and Welfare Grant #15-P-55894. Research on vocational rehabilitation for drug abusers, including support for psychological services and vocational training through Haight Ashbury Free Clinics. National seminar with four-volume proceedings funded by President's Special Action Office for Drug Abuse Prevention.

2. Assistant Principal Investigator, West Coast Polydrug Research and Treatment Project. Investigated patterns of polydrug abuse and provided treatment and training for physicians. Funded by the President's Special Action Office for Drug Abuse Prevention.

3. Associate Principal Investigator, San Francisco Polydrug Project. NIDA grant (number unavailable).

1972-1974

1973-1974

1974-1977

David E. Smith, M.D.

4. Principal Investigator and Director, Amphetamine Evaluation and Physician Training Project. Research on treatment of amphetamine abuse and treatment, including several symposiums and national conference with bound proceedings. Funded by Smith Kline & French.

5. Principal Investigator and Director, PCP Research and Training Project. Research on treatment of PCP abuse and training for physicians and law enforcement including national conference. Diverse government and private funding sources.

5. Co-Director, Drug Abuse and Sexual Dysfunction Research and Physician Training Project. Presented national conference and proceedings. Various funding sources.

6. Co-Principal Investigator and Director, Benzodiazepine Research and Physician Training Project. Developed international physician clinical research network on effects of benzodiazepines at clinical and non-clinical dosages. Resulted in international conference, numerous articles, books and proceedings. Currently used benzodiazepine withdrawal protocol is named the Smith & Wesson Protocol. Funded by Hoffmann LaRoche, Nutley, NT.

7. Director, Impaired Health Professional Research and Training Ongoing clinical research on the treatment of addicted physicians and other health professionals leading to development of diversion and treatment programs for physicians, nurses, and other health professionals. Variable private funding.

8. Co-Principal Investigator, A controlled study of naltrexone maintenance. NIDA Research Grant #R01 DA03516.

9. Principal Investigator, A controlled study of L-tryptophan in cocaine withdrawal. NIDA Research Grant # R01 DA04182.

10. Co-Principal Investigator, A double-blind multi center trial of gepirone and placebo in the treatment of cocaine dependence. Collaborative site study funded by Bristol-Myers Squibb.

11. Co-Principal Investigator, A controlled study of naltrexone induction with clonidine. NIDA Research Grant #R01 DA06038.

11. Co-Principal Investigator, An open usage study of Trexan as adjunctive treatment with psycho social therapy for individuals with alcoholism. Collaborative site study funded by DuPont Merck.

12. Co-Principal Investigator, An observational study on the clinical management of patients treated with naltrexone (ReVia TM ) for alcohol dependence. Collaborative site study funded by DuPont Merck.

13. Co-Principal Investigator, Reducing cocaine relapse with naltrexone, a placebo-controlled, double-blind, randomized clinical trial to test the efficacy of naltrexone for reducing relapse among cocaine abusers who drink alcohol. NIDA Research Grant #R01 DA08871.

14. Consultant, Abuse of Rohypnol in Austin and South Texas, a field work and qualitative data analysis of the phenomenon and scope of Rohypnol abuse in the southern and border areas of Texas. Funded by Hoffmann-LaRoche.

15. Principal Investigator, Fenfluramine/dexfenfluramine use pattern surveillance program. Monitored for development of abuse of fenfluramine or dexfenflurainine. Funded by Wyeth Ayerst.

Page 8

1977- 1979

1978- 1980

1979- 1985

1980- 1985

1980-2006

1985-1989

1987-1991

1990-1991

1990-1994

1993-1995

1995-1996

1995- 1998

1996- 1997

1996-1998


16. Consultant, Tyrosine for methamphetamine dependence, a placebo-controlled, double-blind, randomized clinical trial to test the efficacy of tyrosine as an adjunct to psycho social treatment in abstinence initiation in methamphetamine abusers. NTDA Research Grant No. R01 DA10739.

1996- 1999 17. Co-Principal Investigator, Acamprosate in-patients with alcohol dependence, a double-blind

controlled safety and efficacy study at two active dosage levels. Collaborative site study funded by Lipha Pharmaceuticals.

1997- 1998 18. Consultant, Rohypnol abuse in Florida, a field work and qualitative data analysis of the

phenomenon and scope of Rohypnol abuse in Florida. Funded by Hoffmann-LaRoche. 1997- 1998

19. Co-Principal Investigator, A long-term safety study of SCH 39166 in the treatment of cocaine dependence. Collaborative site study funded by Schering-Plough Research Institute.

1998 20. Consultant, Emerging drugs of abuse in California, a field work and qualitative data analysis

project to investigate new drug abuse patterns in California. Funded by Hoffmann-LaRoche. 1998- 1999

21. Principal Investigator and Medical Director, California State Department of Alcohol and Drug Programs Contract No. 99-00205. Administered through Institute on Health and Aging, UCSF.

1998-2006 22. Co-Investigator, Modafinil use pattern surveillance program. Monitoring for possible development of abuse or

misuse of Modafinil (Provigil TM). Funded by Cephalon, Inc. 1998-2001

23. Consultant, Methamphetamine dependence and the risk of HIV infection, a longitudinal study of in-treatment and out-of-treatment methamphetamine users in San Francisco and Sacramento to examine HIV seroprevalence, seroincidence, risks behaviors, and their antecedents. NIDA Research Grant No. R01DA10641.

1998- 2002 24. Principal Investigator, Technical Assistance - Prevention Outcomes and Measures. California

State Department of Alcohol and Drug Programs Contract No. 98-00253. Administered through Institute for Health and Aging, UCSF.

1999- 2001 25. Principal Investigator, Adolescent Services, California Alcohol and Drug Programs Contract.

Administered through Institute for Health and Aging, UCSF. 2000- 2003

26. Principal Investigator, County Profiles, California Alcohol and Drug Programs Contract. Administered through Institute on Health and Aging, UCSF.

2000-2003 XTV. Bibliography

1. Smith DE & Katzung BG. Mechanical Properties of Hibernating Heart Muscle. American Heart Journal, April, 1966. 2. Smith DE. Lysergic Acid Diethylamide: An Historical Perspective. Journal of Psychedelic Drugs, Volume 1(1), p. 307,

1967. 3. ShubartP, Smith DE & Conrich R. The Concept of Regionalized Health Facility for the Haight-Ashbury Subculture.

Journal of Psychedelic Drugs, Volume 1(1), pp.53-55, 1967. 4. Smith DE. STP: A New Hallucinogen. Monograph - Adverse Reactions to Hallucinogenic .Drags, NIMH Publications,

1967. 5. Smith DE, Fisher CM & Hine CH. Effects of Chlorpromazine Phenobarbital and Iproniazid on the Polyphasic

Mortality Curve of Aggregate Amphetamine Toxicity, Applied Pharmacology, Volume 10, p. 402, March, 1967.

I. )


6. Smith DE. The Role of B Vitamins in Alcoholism Debated. Quarterly Alcohol Review, October, 1967. 7. Smith DE, Fort J & Craton D. Psychoactive Drugs. Journal of Psychedelic Drugs, Volume 1, pp. 150-158, July, 1967. 8. Smith DE & Shubart P. A Regionalized Medical Clinic in the Haight-Ashbury. California's Health, Volume 25(5), pp.

3-6, 1968. 9. Smith DE & Rose AJ. LSD: Its Use, Abuse and Suggested Treatment (Observations by the Haight Ashbury Medical

Clinic). Journal of Psychedelic Drugs, Volume 1(2), pp. 117-123, 1968. 10. Meyer FH & Smith DE. AB1399: Report to the Legislature, California Drug Abuse Treatment and Research

Facilities. California Medicine, September, 1968. 11. SmithDE& MeyerFH. The New Generation and the New Drugs. California's Health,Volume25(S) pp. 7-11,1968. 12. Smith DE. The Role of Nicotinic Acid Derivatives in the Treatment of Acute Toxic Psychosis. Journal of Psychedelic

Drugs, Volume 1(2), pp. 112-114, 1968. 13. Meyer FH, Rose AJ & Smith DE. Incidents Involving the Haight-Ashbury Population and Some Uncommonly Used

Drugs. Journal of Psychedelic Drugs, Volume 1(2), pp. 139-146, 1968. 14. Sankot M & Smith DE. Drug Problems in the Haight-Ashbury. American Journal of Nursing, August, 1968. 15. Smith DE. A View of the Hippie "Non-Student". 1968 Annual Proceedings of the National College Association, April,

1968. 16. Smith DE. Speed Kills - Patterns of High Dose Methamphetamine Abuse. 1968 Annual Proceedings of the National

College Association, April, 1968. 17. Smith DE. Methamphetamine Abusa Bulletin of the Los Angeles County Medical Society, pp. 22-24, June 6, 1968. 18. Smith DE. Youth and Drug Abuse. The Mind Benders, MsGtzv/ Publications, 1968. 19. Smith DE & Rose AJ. Observations in the Haight-Ashbury Medical Clinic of San Francisco - Health Problems in a

Hippie Subculture. Clinical Pediatrics, Volume 6, pp. 313-322, 1968. 20. Smith DE. Speed Kills. Santa Cruz Health Services Proceedings, Student Drug Conference, April, 1968. 21. Smith DE. Contemporary Patterns of Youth and Drug Abuse. Mind Drugs, McGraw Hill Publications, 1969. 22. Smith DE. LSD and the Psychedelic Syndrome. Annual Proceedings of the California Advisory Council on Education

Research, California Journal of Education itesearc/;, November, 1968. 23. Meyer FH & Smith DE. Drug Abuse Recommendations for California Treatment and Research Facilities. California

Medicine,Volume 109, pp. 191-197, 1968. 24. Smith DE. Acute and Chronic Marijuana Toxicity. Journal of Psychedelic Drugs, Volume 2, 1969. 25. Smith DE& BentelDJ. California Drug Scene. The Yearbook of Drug Abuse, Behavioral Publications, New York, p. 157,

1969. 26. Schick F, Meyer FH & Smith DE. Marijuana Use in the Haight-Ashbury Subculture. Journal of Psychedelic Drugs,

Volume 2(1), 1969. 27. Smith DE & Mehl C. An Analysis of Marijuana Toxicity. Clinical Toxicology, March, 1970.


28. Smith DE. Runaways and Their Health Problems in the Haight-Ashbury During the Summer of 1967. American Journal of Public Health, November, 1969.

29. Smith DE. The Characteristics of Dependence in High Dose Methamphetamine Abuse. International Journal of Addictions, Volume 4(3), pp. 453-459,1969.

30. Smith DE. Changing Drug Patterns in the Haight-Ashbury. California Medicine, February, 1969. 31. Smith DE. Speed Freaks vs. Acid Heads: A Conflict Between Drug Subcultures. Clinical Pediatrics, April, 1969. 32. Smith DE. Dependence Characteristics in High Dose Methamphetamine Abuse. International Journal of Addictions,

1969. 33. Smith DE. Youth, Alienation and the Drug Scene. American Journal of Osteopathy, 1969. 34. Smith DE, Wesson D & Lannon R. New Developments in Barbiturate Abuse. Drug Abuse Papers 1969, U.C. Berkeley

Extension, 1969. 35. Smith DE. Narcotics Abuse in San Francisco. Drug Abuse Papers 1969, U.C. Berkeley Extension, 1969. 36. Smith DE. LSD and the Psychedelic Syndrome. Clinical Toxicology, Volume 2(1), pp. 69-73, March, 1969. 37. Smith DE. Physical vs. Psychological Dependence and Tolerance in High Dose Methamphetamine Abuse. Clinical

Toxicology, Volume 2(1), pp. 99-103, March, 1969. 38. Smith DE. The Trip: There and Back. Emergency Medicine, December, 1969. 39. Smith DE & Stages CS. The Semantics of the San Francisco Drug Scene. ETC, Volume 26(2), pp. 168-175, 1969. 40. Smith DE. & Fischer, CM. Acute Amphetamine Toxicity. Journal of Psychedelic Drugs, Volume 2(1), pp. 49-54,1969. 41. Smith DE et al. Behavioral Mediators in the Polyphasic Mortality Curve of Aggregate Amphetamine Toxicity.

Journal of Psychedelic Drugs, Volume 2(2), pp. 28-36,1969. 42. Smith DE. The Psychotomimetic Amphetamines with Special Reference to DOM Toxicity. Journal of Psychedelic

Drugs,pp. 37-41,1969. 42a. Smith DE. An Analysis of Variables in High Dose Methamphetamine Dependence. Journal of Psychedelic Drugs,

Volume 2(2), pp. 60-62, 1969. 43. Schick JF, Smith DE & Meyer FH. The Use of Amphetamine in the Haight-Ashbury Subculture. Journal of Psychedelic

Drugs,pp. 139-171, 1969. 44. Smith DE & Sternfeld JL. Natural Childbirth and Cooperative Child Rearing In Psychedelic Communes. Excerpta

Medica, American Association of Planned Parenthood Physicians, April, 1969. 45. Smith DE & Wesson DR. New Developments in Barbiturate Abuse. Clinical Toxicology, Volume 3(1), pp. 57-65, 1970. 46. Smith DE & Sternfield JL. Natural Childbirth and Cooperative Child Rearing in Psychedelic Communes. Advances in

Planned Parenthood, Volume 4(1), 1970. 47. Smith DE & Sternfield JL. The Hippie Communal Movement: Effects on Childbirth and Development. American

Journal of Orthopsychiatry, Volume 40(3), April, 1970.

David E. Smith, M.D. Paga 12

48. Smith DE & Wesson DR. A New Method for Treatment of Barbiturate Dependence. Journal of the American Medical Association, Volume 213(2), pp. 294-295, February 13,1970.

49. Smith DE, Luce J & Dernberg E. The Health of the Haight-Ashbury. Transaction, April 1970. 49a. Shick JFE & Smith DE. Analysis of the LSD Flashback. Journal of Psychedelic Drugs, Volume 3(1), pp. 13-19, 1970. 49b. Smith DE. LSD, Violence and Radical Religious Beliefs. Journal of Psychedelic Drugs, Volume 3(1), pp. 38-40,1970. 49c. Smith DE & Rose AJ. The Group Marriage Commune: A Case Study. Journal of Psychedelic Drugs, Volume 3(1),

pp. 115-119,1970. 49d. Smith DE & Sternfield JL. Natural Childbirth and Cooperative Child Rearing in Psychedelic Communes. Journal of

Psychedelic Drugs, Volume 3(1), pp. 120-124,1970. 50. Smith DE & Bentel DJ. A New Phenomenon Has Appeared: The Free Clinic. California Health, April, 197'1. 51. Smith DE & Wesson DR. A Phenobarbital Technique for Withdrawal of Barbiturate Abuse. Archives of General

Psychiatry, January, 1971. 52. Bentel DJ& Smith DE. The Year of the Middle Class Junkie. California Health, April, 1971. 53. Sheppard C, Gay GR & Smith DE. Changing Patterns of Heroin Addiction in the Haight-Ashbury. Journal of

Psychedelic Drugs, Volume 3(2), 1971. 54. Bentel DJ & Smith DE. The Crisis of Drugs, Combat and the American Soldier in Vietnam. Synapse, Volume 15(28),

May, 1971. 55. Wesson DR & Smith DE. Barbiturate Use as an Intoxicant - A San Francisco Perspective. Testimony to be presented to

the Subcommittee to Investigate Juvenile Delinquency, Washington D.C., December 15,1971. 56. Wellisch DK, Gay GR, Wesson DR & Smith DE. The Psychotic Heroin Addict. Journal of Psychedelic Drugs, Volume

4(1), 1971. 57. Bentel DR & Smith DE. Drug Abuse in Combat: The Crisis of Drugs and Addiction Among American Troops in

Vietnam. Journal of Psychedelic Drugs, Volume 4(1), pp. 23-30,1971. 58. Wesson DR, Gay GR& Smith DE. Treatment Techniques for Narcotic Withdrawal with Special Reference to Mixed

Narcotic-Sedative Addictions. Journal of Psychedelic Drugs, Volume 4(2), pp. 118-122, 1971. 59. Sheppard CW, Gay GR & Smith DE. Emergency Treatment of Acute Depressant Drug Overdose. Missouri Medicine,

pp. 109-111, February, 1972. 60. Smith DE, Newmeyer J, Gay GR & Corn R. Methadone for Kicking and for Kicks. Published for the 4th Annual

Methadone Conference, January 10, 1972. 61. Gay GR, Smith DE & Sheppard CW. Yesterday's Flower Child is Today's Junkie. Medical Insight, pp. 45-50, March,

1972. 62. Wesson DR, Gay GR & Smith DE. Managing Narcotic and Sedative Withdrawal. Hospital Physician, pp. 52-55,

January, 1972. 63. Schick JF & Smith DE. Analysis of the LSD Flashback. Journal of Psychedelic Drugs, Volume 3(1), 1972.


64. Smith DE. A Physician's View of the Adolescent Drug Scene. Drug Abuse Proceedings of the International Conference, pp. 271-275,1972.

65. Smith DE. Sexual Practices in the Hippie Subculture. Medical Aspects of Human Sexuality, pp. 142-151, April, 1972. 66. Smith DE & Gay GR. Medical Care of Psychotropic Drug Problem Patients Outside the Hospital. World Medical

Journal, Volume 19(2), March-April, 1972. 67. Smith DE, Gay GR& Einstein S. Acute Drug Reactions in Perspective. The Non-Medical Use of Drugs: Contemporary

Clinical Issue, Number 1, pp. 47-55, 1972. 68. Shick JF, Smith DE & Wesson DR. The Illicit Use of the Psychotomimetic Amphetamines with Special Reference to

STP (DOM) Toxicity. Journal of Psychedelic Drugs, Volume 5(1), 1972. 69. Shick JF, Smith DE & Wesson DR. Amphetamine Toxicity with Analysis of Patterns of Use and Abuse. Journal of

Psychedelic Drugs, Volume 5(1), 1972. 70. Gay GR, Wesson DR, Smith DE & Sheppard CW. Outpatient Barbiturate Withdrawal Using Phenobarbital.

International Journal of Addictions, Volume 7(1), pp. 17-27, 1972. 71. Sheppard CW, Smith DE & Gay GR. The Changing Face of Heroin Addiction in the Haight-Ashbury. International

Journal of Addictions, pp. 109-123, 1972. 72. Smith DE. The Free Clinic. The Federal Challenge to the Community: A Health and Education Program for the

Prevention and Treatment of Drug Abuse and Addiction, Wadler et al, 1972, 73. Wesson DR, Gay GR & Smith DE. Clinical-Political Issues of Barbiturate Use and Abuse. Contemporary Drug

Problems, pp. 453-465, Summer, 1972. 74. Ramer BS, Smith DE & Gay GR. Adolescent Heroin Abuse in San Francisco. International Journal of the Addictions,

Volume 7(3), pp. 461-465,1972. 75. Newmeyer JA, Gay GR, Corn R & Smith DE. Methadone for Kicking and for Kicks. Fourth National Conference on

Methadone Treatment: Proceedings, National Association for the Prevention of Addiction to Narcotics (NAP AN), pp, 461-464,1972.

76. Shick JF & Smith DE. The Llicit Use of the Psychotomimetic Amphetamines with Special Reference to STP (DOM) Toxicity. Journal of Psychedelic Drugs, Volume 5(2), pp. 131-138, Winter, 1972.

77. Wesson DR & Smith DE. Recognizing and Treating Amphetamine Abuse. Hospital Physician, pp. 22-25, August, 1973. 78. Smith DE. Patterns of Drug Abuse in Industry. Drug Abuse in Industry, Published by Charles C. Thomas, Springfield,

pp. 49-55. 1973. 79. Shick JF, Smith DE & Wesson DR. An Analysis of Amphetamine Toxicity and Patterns of Use. Journal of Psychedelic

Drugs, Volume 5(2), pp. 113-130, Winter, 1973. 80. Smith DE & Case L. Drug Abuse. Family Practice Textbook, W.B. Saunders & Co., pp. 259-264,1973. 81. Eiswirth NA, Smith DE & Wesson DR. Current Perspectives on Cocaine Use in America. Journal of Psychedelic Drugs,

Volume 5(2), pp. 159-166, 1973. 82. Wesson DR & Smith DE. Barbiturate Toxicity and the Treatment of Barbiturate Dependence. Journal of Psychedelic

Drugs, Volume 5(2), pp. 159-166, 1973.

David E. Smith, M.D. Pags 14

83. Wesson DR & Smith DE. Methaqualone: Just Another Downer. Journal ofPsychedelic Drugs, Volume 5(2), pp. 167-170, 1973.

84. Wesson DR, Gay GR & Smith DE. The Politics of Barbiturate and Amphetamine Abuse. Journal of Psychedelic Drugs, Volume 5(2), pp. 177-182,1973.

85. Smith DE & Wesson DR. Legitimate and Illegitimate Distribution of Amphetamines and Barbiturates. Journal of Psychedelic Drugs, Volume 5(2), pp. 177-182,1973.

86. Smith DE, Loomis S, Jacobs-White L, Bricker B, Singleton J, Linda L. The Haight Ashbury Free Medical Clinic: Approach to a Community Based Drug Rehabilitation Program. Vocational Rehabilitations of the Drug Abuser, Book 2, pp. 2-38, 1973.

87. Smith DE, Wesson DR&CiceriR. The National Free Clinic Movement: Historical Perspective. ADIT, Volume 2(3), pp. 1-2,12-16, October, 1973.

88. Smith DE. The Free Clinic Movement in the United States. World Medical Journal, Volume 21(3), May- June, 1973. 89. Smith DE, Linda L, Loomis S, Jacobs-White L, Bricker B & Singleton J. A Community Based Drug Abuse

Rehabilitation Program in the Haight Ashbury. Preventive Medicine, Volume 2, pp. 529-542,1973. 90. Smith DE & Wesson DR. Diagnosis and Treatment of Adverse Reactions to Sedative-Hypnotics. National Institute on

Drug Abuse Manual,No. 74-24, 1973. 91. Smith DE, Gay GR&Shepherd CW. The New Junkie. Emergency Medicine, Volume 6(2), pp. 117-126, February, 1974. 92. Smith DE & Wesson DR. Drugs of Abuse 1973: Trends and Developments. Annual Review of Pharmacology. Palo

Alto.CA, pp. 513-520,1974. 93. Smith DE, Wesson DR& Linda L. Drug Crisis Intervention: Conceptual and Pragmatic Considerations. Journal of

Psychedelic Drugs, Volume 6(2), April-June, 1974. 94. Smith DE. Street Drug Analysis and Community Based Drug Programs. Journal of Psychedelic Drugs, Volume 6(2),

April-June, 1974. 95. Smith DE & Wesson DR. A Conceptual Approach to Detoxification. Journal of Psychedelic Drugs. Volume 6(2), April-

June, 1974. 96. Smith DE, Loomis S & Linda L. Experiences of the Haight Ashbury Free Medical Clinic's Community Based Drug

Program. Journal of Psychedelic Drugs, Volume 6(2), 1974. 97. Smith DE. The Evolution of Counter-Culture Street Drug Analysis Programs. Street Drug Analysis andlts Social and

Clinical Implications, The Addiction Research Foundation, pp. 1-8, Ontario, Canada, 1974. 98. Smith DE. West Coast Research/Findings Into Polydrug Abuse and Problems Associated with the Use of Non-

Opiates. Proceedings: 1974 Ohio Ding Studies Institute, Bureau of Drug Abuse, pp. 7-13,1974. 99. Smith DE & Gay GR. The Development of Drug Patterns and Treatment Techniques in a Free Clinic. The Free Clinic

Handbook. Volume 30(1), pp. 127-142,1974. 100. Smith DE, Wesson DR, Lerner SE & Ketlner VR. Treatment of Polydrug Users in San Francisco. The American Journal

of Drug and Alcohol Abuse, Volume 1(2), pp. 159-179, 1974. 101 .Smith DE & Wesson DR. Chronic Polydrug Abuse Among the "Non-Streetwise." Newsletter, California Society for the

Treatment of Alcoholism and Other Drug Dependencies, Volume 2(1), January, 1975.


102,Smith DE & Gay GR. A Free Clinic Approach to Drug Abuse. Preventive Medicine, Volume 2, pp. 543-553, 1975. 103.Smith DE. The Role of the Free Clinic in America's Changing Health Care Delivery System. Journal of Psychedelic

Drugs, Volume 7(1), January-March, 1975. 104.Smith DE. Special Treatment and Service Needs of Youthful Drug Abuses. Final Report: A Survey of New Techniques

for the Treatment of Drug Abusers, NIDA, Volume 2, Chapter 10, January, 1975. 105.Smith DE & Skeen E. Innovative Programming for the Drug Misusing Adolescent. Crime and Corrections: Journal of

the California Probation, Parole and Correctional Association, Volume 3(1), pp. 11-20, 1975. 106.Smith DE, Wesson DR & Yatsu FM. Amphetamine Abuse. Medical Aspects of Drug Abuse, pp. 50-56, 1975. 107.Smith DE & Wesson DR. Editor's Note. Journal of 'Psychedelic Drags, Volume 7(2), pp. 111-114, 1975. 108. Wesson DR, Smith DE & Lerner SE. Streetwise and Nonstreetwise Polydrug Typology: Myth or Reality. Journal of

Psychedelic £>rugj, Volume 7(2), pp. 121-134,1975. 109. Wesson DR, Smith DE & Lerner SE. The Treatment of the Polydrug Abuse in San Francisco with Discussion of Youth

and Polydrug Abuse. Catalog of Selected Documents in Psychology, Volume 5, American Psychological Association, pp. 228, 1975.

HO.Smith DE. Community Approaches to Drug Abuse Treatment and Rehabilitation. Proceedings, Ohio Drug Studies Institute, pp. 42-51, June, 1975.

111. Smith DE & DeRios MD. Using or Abusing? An Anthropological Approach to the Study of Psychoactive Drugs. Journal of Psychedelic Drugs, Volume 8(3), p. 263-266,1976.

112.Smith DE. Rand Report Commentary. Newsletter, California Society for the Treatment of Alcoholism and Other Drug Dependencies, Volume 3(4), 1976.

113. Smith DE. The Free Clinic Movement In the United States: A Ten Year Perspective. Journal of Drug Issues: Retrospective and Prospective. Part I, pp. 343-355, Fall, 1976.

114.Smith DE & Wesson DR. Managing the Barbiturate Withdrawal Syndrome. Acute Drug Abuse Emergencies, pp. 99-104,1976.

115.Smith DE & Wesson DR. An Analysis of Psychedelic Drug Flashbacks. American Journal of Drug and Alcohol Abuse, Volume 3(3), pp. 425-438.

116.Smith DE & Wesson DR. Psychoactive Drug Crisis Intervention. Current Psychiatric Therapies, Volume 16, pp. 203-208,1976.

117.SmithDE. Multiple Substance Abuse - The New Face of Addiction. Contemporary Drug Problems: Proceedings of the Ninth Annual Eagleville Conference, Volume 5(3), Fall, 1976.

118. Smith DE. The Disabled Physician. Proceedings for the 4th Annual Iowa Conference on Substance Use and Misuse, pp. 74-76, December 2-3,1976.

119. Smith DE. Characteristics in Substance Abuse. Prescription Drugs and the Potential for Dependence, Exerpta Medica, pp. 308, 1977.

120.Smith DE, Wesson DR, Kramer J, deRios M. Editor's Note. Journal of Psychedelic Drugs, Volume 9(3), pp. 185-186, July-September, 1977.


121.Smith DE & Wesson DR. Cocaine: Its Use for Central Nervous System Stimulation Including Recreational and Medical Uses. Research Monograph Series 13: Cocaine 1977, National Institute on Drug Abuse, pp. 137-152, May, 1977.

122. Smith DE. Clinical Guidelines for Drug Detoxification. Gladman Psychiatric Hospital, Haight Ashbury Publications, 1977.

123.Smith DE. Lead Poisoning, Environmental Health and Social Class. The Mississippi Enterprise, Volume 45(42), p. 2, July 30, 1977.

124.Smith DE. Treatment Techniques and the Dependent Physician. Helping the Impaired Physician. Proceedings of the AMA Conference on "The Impaired Physician: Answering the Challenge", pp. 49-54, February, 1977.

125. Smith DE & Seymour RB. The Haight Ashbury Free Medical Clinic: A Ten Year Perspective. San Francisco Medicine, 1977.

126.SmithDE. Physician's Attitudes Concerning Drug Abuse Treatment. Polydrug Abuse, The Results of a National Collaborative Study, Academic Press, Inc., New York, 1978.

127.Smith DE & Wesson DR. Barbiturates and Other Sedative-Hypnotics. Treatment Aspects of Drug Dependence, pp. 117-

130, CRC Press, Inc., 1978. 128.Smith DE & Wesson DR. CNS Stimulants. Treatment Aspects of Drug Dependence, pp. 131-146, CRC Press, Inc., 1978. 129.Smith DE & Wesson DR. Psychedelics. Treatment Aspects of Drug Dependence, pp. 146-160, CRC Press, Inc., 1978. 130.SmithDE. Editor's Note. Journal of Psychedelic Drags, Volume 10(3), 1978. 131. Smith DE. A Clinical Approach to Diagnosis and Treatment of Amphetamine Abuse. Journal of Psychedelic Drugs,

Volume 10(4), 1978. 132.Smith DE. Cocaine. Journal of Psychedelic Drugs, Volume 10(4), 1978. 133.Smith DE. Substance Abusing Physicians as Patients: Unique Aspects of Treatment Conference Proceedings, March,

1978. 134.Smith DE. Editor's Note. A Multicultural View of Drug Abuse, Proceedings of NDAC 77, G.K. Hall, 1978. 135.SmithDE, Cocaine Abuse: 1977. A Multicultural View of Drug Abuse. Proceedings of theNDAC77, G.K. Hall, pp. 116-

131, 1978. 136.Smith DE. The Practicing Physicians View of the Alcohol and Drug Abuse Patient: A Training and Consultation

Model for Analysis and Change. A Multicultural View of Drug Abuse, Proceedings of NDAC 77, G.K. Hall, pp. 246-262, 1978.

137. Smith DE, Levy SJ & StriarDE. Treatment Services for Youthful Drug Users. Youth Drug Abuse, Problems, Issues and Treatment, pp. 537, 1978.

13 8. Smith DE, Wesson DR & Seymour RB. The Abuse of Barbiturates and Other Sedative-Hypnotics. Handbook on Drug Abuse, National Institute on Drug Abuse and Executive Office of the President, Washington DC, 1979.

139. Smith DE & Seymour RB. The Enigma of Paraquat Contaminated Marijuana. The Street Pharmacologist, Volume 2(1), 1979.

J )


140. Smith DE, Wesson DR, Seymour RB, Buxton ME & Kramer HM. The Diagnosis and Treatment of the PCP Abuse Syndrome. Phencyclidine (PCP) Abuse: An Appraisal. National Institute on Drug Abuse, Rockville, Maryland, 1978.

141. Smith DE, Wesson DR, Seymour RB, Buxton ME & Kramer HM. The Diagnosis and Treatment of the PCP Abuse Syndrome. Phencyclidine (PCP) Abuse: An Appraisal. National Institute on Drug Abuse, Rockville, Maryland, 1978.

142.Smith DE, Buxton ME & Dammann G. Amphetamine Abuse and Sexual Dysfunction: Clinical and Research Considerations. Amphetamine Use, Misuse and Abuse, Proceedings of the National Amphetamine Conference 1978, G.K. Hall, pp. 228-250, 1979.

143. Chappel J, Smith DE & Buxton ME. Training Techniques for Physicians in the Diagnosis and Treatment of Amphetamine Abuse. Amphetamine Use, Misuse and Abuse, Proceedings of the National Amphetamine Conference 1978, G.K. Hall, pp. 251-259, 1979.

144. Wesson DR & Smith DE. A Clinical Approach to Diagnosis and Treatment of Amphetamine Abuse. Amphetamine Use, Misuse and Abuse, Proceedings of the National Amphetamine Conference 1978, G.K. Hall, pp. 260-276,1979.

145.Smith DE & Wesson DR. Cocaine. Interamerican Seminary About Coca and Cocaine - Medical and Sociological Aspects. pp., 49-61, Lima, Peru, July, 1979.

146. Smith DE. Drug Abuse Patterns on the West Coast. Proceedings, New York Academy of the Sciences Drug Abuse Conference, December, 1979.

147.Smith DE. Importance of Gradual Dosage Reduction Following Low-Dose Benzodiazepine Therapy. Newsletter, California Society for the Treatment of Alcoholism and Other Drug Dependencies, Volume 6(2), April, 1979.

148.Smith DE. Editor's Note. Journal of Psychedelic Drugs, Volume 12(3-4), pp. 181-184,1979. 149.Smith DE, Smith N, Buxton ME & Moser C. PCP and Sexual Dysfunction. Journal of Psychedelic Drugs, Volume 12(3-

4), pp. 269-274,1979. 150.SmithDE& Wesson DR. PCP Abuse: Diagnostic and Psychopharmacological Treatment Approaches. Journal of

Psychedelic Drugs, Volume 12(3-4), pp. 293-300,1979. 151. Chappel J, Smith DE & Buxton ME. Paraprofessional and Professional Teamwork and Training in Managing PCP

and Other Drug Abuse Problems. Journal of Psychedelic Drugs, Volume 12(3-4), pp. 301-306, 1979. 152. Smith DE, Wesson DR & Linda L. Clinical Approaches to Acute and Chronic Intervention in the Sedative-Hypnotic

Abuser. Drugs in Relation to the Drug User -Critical Drug Issues, pp. 192-243, 1980. 153.Smith DE. Persian Heroin in the San Francisco Bay Area, 1977-1980: The New Wave? Newsletter, California Society

for the Treatment of Alcoholism and Other Drug Dependencies, Volume 7(2), April, 1980. 154. Seymour RB, Smith DE & Corhacchia HJ. Status of Drug Education Programs in the United States -1980. Unify for

the 80's: Tlw Official Proceedings of the National Alcohol and Drug Coalition. The Hayworth Press, Inc. New York, 1980. 155. Smith DE & Seymour RB. Prescribing Practices: The Educational Alternative for Misprescribers. Proceedings of the

White House Conference on Prescription Drug Abuse, Washington DC, 1980. 156.Smith DE & Seymour RB. The Prescription of Stimulants and Anorectics. Frequently Prescribed and Abused Drugs:

Their Indications, Efficacy and Rational Prescribing. Medical Monograph Scries, National Institute on Drug Abuse, Rockville, Maryland, 1980.

157. Smith DE. A Clinical Approach to the Treatment of PCP. PCP (Phencyclidine): Historical and Current Perspectives, Chapter 22, NPP Books, Ann Arbor, Michigan, 1981.


158.Smith DE. Drugs and Sexual Function. Sexual Problems in Medical Practice, American Medical Association, Chapter 17, pp. 211-242, 1981.

159.Smith DE. Prescription Drugs and the Alcoholic: The Benzodiazepines - Therapeutic and Dependence Considerations. Proceedings of the Eisenhower Medical Center and the California Society for the Treatment of Alcohol and Other Drug Dependencies, pp. 42-48, Winter, 1981.

160, Smith DE. Polydrug Abuse and Comprehensive Treatment Intervention. National Clearinghouse for Drug Abuse Information, Rockville, Maryland, 1981.

161.Smith DE& Buxton ME. Women and Substance Abuse: Treatment Issues. Women in Crisis, Human Sciences Press, Chapter 12, pp. 101-107, New York, 1981.

162.SmithDE & Buxton RB. Psychedelics. Tire Patient with Alcoholism and Other Drug Problems: A Clinical Approach for Physicians and Helping Professionals, Yearbook Medical Publishers, Chicago, Illinois, 1981.

163.Smith DE & Seymour RB. Clinical Perspectives on the Toxicity of Marijuana, 1967-1981. Marijuana and Youth: Clinical Observations on Motivation and Learning, National Institute on Drug Abuse, Rockville, Maryland, 1982.

164.Seymour RB, Smith DE & Gorton JG. The Client with a Substance Abuse Problem. Practice and Management of Psychiatric Emergency Room Care, C.V. Mosby Company, St. Louis, Missouri, 1982.

165.Smith DE. Sedative Misuse and Dependence. The Patient with Alcohol and Drug Abuse Problems. C. Whitfield, pp. 33-354, 1982.

166.SmithDE. Editor's Introduction. Proceedings, Volume 14(1-2), January-June, 1982. 167. Smith DE. A Clinical Guide to the Diagnosis and Treatment of Heroin-Related Sexual Dysfunction. Proceedings,

Volume 14(1-2), January-June, 1982. 168.Smith DE & Seymour RB. Abuse Folio: High Tunes Desk Reference; Amphetamine Look-Alikes. High Times,

Number 80, p. 30, April, 1982. 169.Smith DE & Seymour RB. Abuse Folio: High Times Desk Reference; Glutethimide and Codeine. High Times, Number

81, p. 30, June, 1982. 170.Smith DE & Seymour RB. Abuse Folio: High Times Desk Reference; Persian Heroin. High Times, Number 82, p. 30,

June, 1982. 171 .Smith DE & Seymour RB. Abuse Folio: High Times Desk Reference; Alpha Metyl Fentanyl. High Times, Number 83,

p. 30, June, 1982. 172.Smith DE & Seymour RB. Abuse Folio: High Times Desk Reference; Cocaine Freebase. High Times, Number 84,

August, 1982. 173.Smith DE & Seymour RB. Abuse Folio: High Times Desk Reference; Lysergic Acid Diethylamide. High Times,

Number 85, September, 1982. 174. Smith DE& Seymour RB. Abuse Folio: High Times Desk Reference; Marijuana. High Times, Number 86, October,

1982. 175.Smith DE & Seymour RB. Abuse Folio: High Times Desk Reference; Alcohol. High Times, Number 87, November,

1982.


176.SmithDE& Seymour RB. Abuse Folio: High Times Desk Reference; Valium. High Times, Number 88, December, 1982.

177.Smith DE & Seymour RB. Clinical Perspectives on the Toxicity of Marijuana, 1967-1981. Marijuana and Youth: Clinical Observations on Motivation and Learning, U.S. Department of Health and Human Services Publication, Washington DC, pp. 61-72, 1982.

178.Smith DE, Seymour RB & Gorton JG. The Client With a Substance Abuse Problem. Practice and Management of Psychiatric Emergency Care, C.V. Mosby Company, St. Louis, Missouri, 1982.

179.Smith DE & Yeary J. Dealing With Family Problems Caused by Alcohol. Medical Aspects ofHuman SexualHy,Wolvane 16(11), November, 1982.

180.Smith DE. Diazepam as Black Market Quaaludes. Newsletter, California Society for the Treatment of Alcoholism and Other Drug Dependencies, Volume 9(3-4), October, 1982,

181. Smith DE. Diagnosis and Treatment of Cocaine Abuse. Proceedings, Symposium on Cocaine Abuse, New York State Division of Substance Abuse Services Narcotic Drug Research, Inc., May, 1982.

182. Buffum J, Moser C & Smith DE. Street Drugs and Sexual Function. Handbook of Sexology: The Pharmacology and Endocrinology of Sexual Functions, Elsevier Scientific Publications, pp. 462-477,1982.

183,SmithDE& Seymour RB, Prescribing Psychoactive Drugs: A Question of Perspective. Society and Medication: Conflicting Signals of Prescribers and Patients, Lexington Books, Lexington, 1983.

184.Smith DE. Treatment Considerations with Cocaine Abusers. Cocaine: A Second Look, American Council on Marijuana, 1983.

185.Smith DE & Seymour RB. Abuse Folio: High Times Desk Reference; Benzodiazepines. High Times, No. 89, January, 1983.

186.Smith DE & Seymour RB. Abuse Folio: High Times Desk Reference; Acupuncture and Addiction. High Times, No. 90, February, 1983.

187.Smith DE & Seymour RB. Abuse Folio: High Times Desk Reference; MDA. High Times, No. 90, March, 1983. 188.Smith DE & Seymour RB. Abuse Folio: High Times Desk Reference; Amphetamines. High Times, No. 91, April, 1983. 189.Smith DE & Seymour RB. Abuse Folio: High Times Desk Reference; Psilocybin. High Times, No. 92, May, 1983. 190.Smith DE & Seymour RB. Abuse Folio: High Times Desk Reference; Talwin and Tripelennamine. High Times, No. 93,

June, 1983. 191.Smith DE & Seymour RB. Abuse Folio: High Times Desk Reference; Amyl, Butyl and Isobutyl Nitrite. High Times,

No. 94, July, 1983. 192. Smith DE & Seymour RB. Abuse Folio: High Times Desk Reference; Phencyciidines. High Times, No. 95, August,

1983. 193.Smith DE & Seymour RB. Abuse Folio: High Times Desk Reference; AIDS, Part 1. High Times, No. 96, September,

1983. 194.Smith DE & Seymour RB. Abuse Folio: High Times Desk Reference; AIDS, Part 2. High Times, No. 97, October, 1983. 195.Smith DE & Seymour RB. Abuse Folio: High Times Desk Reference; Nicotiana Tabacum. High Times,No.9$,

November, 1983.

•avid E. Smith, M.D. Page 20

196. Smith DE & Seymour RB. Abuse Folio: High Times Desk Reference; Caffeine. High Times, No. 99, December, 1983. 197. Smith DE. Intervention Techniques for the Physician with a Substance Abuse Disorder. San Francisco Medicine, San

Francisco Medical Society, September, 1983. 198.Smith DE. Benzodiazepine Dependency Syndromes. Proceedings, Volume 15(1-2), 1983.

199.Smith DE. Diagnostic, Treatment and Aftercare Approaches to Cocaine Abuse. Journal of Substance Abuse Treatment, Volume 1(1), 1984.

200.Smith DE & Seymour RB. Abuse Folio: High Times Desk Reference; D.O.B. High Times, No. 100, January, 1984. 201 .Smith DE & Seymour RB. Abuse Folio: High Times Desk Reference; Cocaine. High Times, No. 101, February, 1984 202. Smith DE & Seymour RB. Abuse Folio: High Times Desk Reference; Cocaine Look Alikes. High Times, No. 102,

March, 1984. 203.Smith DE. Substance Abuse Disorders: Drugs and Alcohol Review of General Psychiatry, Lange Medical Publishers,

Los Altos, California, 1984. 204.Smith DE & Seymour RB. Abuse Folio: High Times Desk Reference; MPTP. High Times, No. 103, April, 1984. 205. Smith DE & Seymour RB. Abuse Folio: High Times Desk Reference; Heroin. High Times,No. 104, May, 1985. 206.Smith DE & Seymour RB. Abuse Folio: High Times Desk Reference; Volatile Hydrocarbons. High Times, No. 105,

June, 1984. 207.Smith DE & Seymour RB. Abuse Folio: High Times Desk Reference; Methaqualone. High Times, No. 106, July, 1984. 208.Smith DE & Seymour RB. Abuse Folio: High Times Desk Reference; Barbiturates. High Times, No. 107, August, 1984 209.Smith DE & Seymour RB. Abuse Folio: High Times Desk Reference; Mescaline/Peyote. High Times, No. 108,

September, 1984. 210.Smith DE. Sexual Effects of Illicitly Used Drugs. Physician and Patient, Volume 3(5), May, 1984. 211. Smith DE. Benzodiazepine Dependence Potential: Current Studies and Trends. Journal of Substance Abuse Treatment,

1984. 212. Smith DE. Look Alike Drugs and Drugs of Deception: Epidemiological, Toxicological and Clinical Considerations,

1984. 213.Smith DE, Apter-Marsh M, Buffum J, Moser C & Wesson DR. Socio-Sexual Issues in the Using and Recovering

Alcoholic. Alcoholism Treatment Quarterly, Volume 1(3), Fall, 1984. 214SmithDE& Wesson DR. Substance Abuse in Industry: Intervention, Treatment and Prevention. Substance Abuse

in the Workplace, Haight Ashbury Publications, San Francisco, 1984. 215.Smith DE. Cocaine and Alcohol Induced Sexual Dysfunction. Proceedings, Volume 16(1-2), October-December, 1984. 216.Smith DE, Milkman H & Sunderwirth S. Addictive Disease: Concept and Controversy. The Addictions. Lexington

Books, Lexington, Massachusetts, 1984. 217.Seymour RB & Smith DE. AClinical Update on Illicit and Prescription Drugs - 1984. San Francisco Medicine, 1984.


218,SmithDE& Seymour RB. Marijuana, Addictive Disease and Recovery. Drug Use in Society: Proceedings of Marijuana and Health Conference, Council on Marijuana and Health, Washington DC, 1984.

219.Smith DE. Controversies Surrounding the Emergence of Addictionoiogy as a Specialty. Newsletter, California Society for the Treatment of Alcoholism and Other Drug Dependencies, June, 1985.

220.Srnith DE, Seymour RB, Morgan JP & Kagan DV. Prescription Psychoactive Drugs: A Question of Perspective. Social and Medical Signals for Prescribers andPatients, Chapter 16, 1985.

221.Smith DE & Seymour RB. The Dream Becomes a Nightmare: Adverse Reactions to LSD. Journal of Psychoactive Drags, Volume 17(4), 1985.

222.SmithDE & Seymour RB. Clarification of Designer Drugs. The U.S. Journal ofDrug andAlcohol Abuse, November, 1985.

223. Smith DE. Look-Alike Drugs and Drugs of Deception: Epidemiological, Toxicological and Clinical Considerations. Phenylpropanolamine: Risks, Benefits and Controversies, Volume 5, 1985.

224.Smith DE & Seymour RB. Nonmedical Prescription Drug Use. Topics in Clinical Pharmacology and Therapeutics, 1985. 225.Smith DE. 1984: A Clinical Update on Illicit and Prescription Drug Abuse. San Francisco Medicine, San Francisco

Medical Society, January, 1985. 226.SmithDE& Wesson DR. MDMA: Ecstasy as an Adjunct to Psychotherapy and a Street Drug of Abuse. California

Society for the Treatment of Alcoholism and Other Drug Dependencies News, September, 1985. 227.Smith DE & Seymour RB. A Clinical Approach to the Impaired Health Professional. The International Journal of the

Addictions. Volume 20(5), pp. 713-722, 1985. 228.Smith DE, Seymour RB. Focus on Illicit Drugs: Clarification of Designer Drugs, U.S Journal of Alcohol and Chemical

Dependence, November, 1985. 229.Smith DE, Wesson DR, Camber S & Harley M. Diazepam and Desmethyldiazepam in Breast Milk. Journal of

Psychoactive Drugs, Volume 17(1), pp. 55-56, January-March, 1985. 230.Smith DE. Cultural Contrasts In Drug Abuse. I/. 5". Journal of Alcohol and Chemical Dependence, p. 7, December, 1986. 231. Smith DE, Havassy BE & Wesson DR. Theories of Relapse and Recovery and Their Implications of Drug Abuse

Treatment. Relapse and Recovery in Drug Abuse. NTDA Research Monograph 72,1986. 232. Zweben JE & Smith DE. Changing Attitudes and Policies Toward Alcohol Use in the Therapeutic Community.

Journal of Psychoactive Drugs, Volume 18(3), 253-259, 1986. 233.Smith DE. Cocaine-Alcohol Abuse: Epidemiological, Diagnostic and Treatment Considerations. Journal of

Psychoactive Drugs, Volume 1,1986. 234.Smith DE & Seymour RB. Look Alike Drugs, Drags of Deception and Designer Drugs. The Narc Officer, Official

Publications of the International Narcotics Enforcement Officers Association, Spring, 1986. 235.Smith DE& Wesson DR. Substance Abuse in Industry: Identification, Intervention, Treatment and

Prevention. The Narc Officer, Spring, 1986. 236.Wesson DR, Smith DE & Morgan JP. The International Scheduling of OTC Inhaler Ingredients: An Abuse

Perspective. Journal of Psychoactive Drugs, Volume 18(2), pp. 151-154, 1986.

)

•avid E. Smith, M.D. Pago 22

237.Smith DE & Seymour RB. Look Alike Drugs, Drugs of Deception and Designer Drugs. The Narc Officer, pp. 57-62, Spring, 1986.

238.Smith DE, Wesson DR & Gold MS. Cocaine Abuse and Treatment: A Starting Point. Psychiatry Letter, Volume 4(11), pp. 55-64,1986.

239.Smith DE & Seymour RB. Barbiturate/Sedative/Hypnotic. Psychiatric Treatment Manual, American Psychiatric Association, New Haven, Connecticut, 1986.

240. Smith DE & Seymour RB. Non Medical Prescription Drug Use. Topics in Clinical Pharmacology and Therapeutics. Springer-Verlag, Inc, New York, 1986.

241. Smith DE. Chemical Dependency and AIDS. AIDS and Chemical Dependency Forum, San Francisco, California, April,

242. Wesson DR, Smith DE & Morgan JP. International Scheduling of the OTC Inhaler Ingredients: An Abuse Perspective Journal of Psychedelic Drugs, Volume 18(2), pp. 151-54, April-June, 1986.

243. Smith DE. Role of Substance Abuse Professionals in the ADDS Epidemic, written for the American Medical Society of Alcohol and other Drug Dependence, February, 1987.

244. Landry MJ & Smith DE. Crack: Anatomy of an Addiction. California Nursing Review, Volume 9(2), pp. 8-47,1987. 245. Buxton ME, Smith DE & Seymour RB. Spirituality and Other Points of Resistance to the 12 Step Recovery Process.

Journal of Psychoactive Drugs, Volume 19(3), pp. 275-286,1987. 246. Smith DE, Apter-Marsh M, Buffum J, Moser C & Wesson DR. Recovering Alcoholics in Family Practice. Medical

Aspects of Human Sexuality, pp. 86-94, July, 1987. 247.Smith DE. Alcoholism, Recovery & Sexual Dysfunction. Psychiatiic Medicine, Volume 3(3), pp. 163-172, 1987. 248.Smith DE. Teach, Bleach & Treat: AIDS Outreach. Medical Society of Addiction Medicine Conference, 1987. 249. Smith DE. Role of the Hospital Well Being Committee. San Francisco Medicine, pp. 25-40, January, 1987. 250. Smith DE & Landry MJ. AIDS and Chemical Dependency: An Overview. Journal of Psychoactive Drugs, Volume 20(2),

April-June, 1988. 251. Smith DE. Should the U.S. Legalize Narcotics? U. S. Journal of Alcohol and Chemical Dependence, Volume 12(8),

August, 1988. 252. Smith DE & Heilig S. Addiction Update 1988: Treatable Diseases. San Francisco Medicine, Volume 32(2), August,

1988. 253.Landry MJ& Smith DE. AIDS and Chemical Dependency: An Overview. Journal of Psychoactive Drugs, Volume

20(2), pp. 141-147,1988. 254,Smith DE, Wesson DR, Sees KL & Morgan JP. An Epidemiological and Clinical Analysis of Propylhexedrine Abuse in

the United States. Journal of Psychoactive Drugs, Volume 20(4), pp. 441-442, 1988. 255.Smith DE & Wesson DR. Substance Abuse in Industry: Identification, Intervention, Treatment and Prevention, 1988. 256.Smith DE & Landry MJ. Psychoactive Substance Use Disorders: Drugs and Alcohol. General Psychiatry, Second

Edition, pp. 266-285, 1988.

1986.


257.Smith DE & Seymour RB. Clinical Issues on Drugs and the Law. Perspectives on Drug Abuse - Volume I, Freund Publishing House, Tel Aviv, 1988.

258.Smith DE. The Addictive Disease: Controversy and Understanding. Conference Address, 1989. 259.SmithDE & Seymour RB. The Evolution of Drug Use: The Changing Street Drug Scene. California Pharmacist,

August, 1989. 260. Smith DE. From the 60's to the 90's: The Evolution of Chemical Dependency Treatment. The Counselor, September-

October, 1989. 261.Smith DE. Hazards of Cocaine Becoming Notorious. U.S. Journal of Alcohol and Chemical Dependence, Volume 13(5),

May, 1989. 262.Smith DE & Zweben, JE. Considerations in Using Psychotropic Medicine with Dual Diagnosis Patients in Recovery.

Journal of Psychoactive Drugs, Volume 21(2), pp. 221-228, April-June, 1989. 263. Smith DE & Heilig S. Addiction Medicine Alert. San Francisco Medicine, Volume 19, November, 1989. 264. Smith DE, Wesson DR, Camber S & Landry MJ. Perceptions of Benzodiazepine and Cocaine Abuse by US Addiction

Specialists. National Directorate for Prevention of Alcohol and Drug Problems, Volume 4, pp. 371-390,1989. 265.Smith DE, Wesson DR & Landry MJ. The Pharmacology of Benzodiazepine Addiction. Selective Therapeutic Index,

Volume 2(9), pp. 94-107, September, 1989. 266.SmithDE. Addiction Medicine and Primary Care. Western Journal of Medicine, May, 1990. 267.Smith DE & Wesson DR. Prescription Drug Abuse: Patient, Physician and Cultural Responsibilities. Western Journal

of Medicine, Volume 152, pp. 613-616, May 1990. 268,Landry MJ & Smith DE. Benzodiazepine Dependency Discontinuation: Focus on the Chemical Dependency

Detoxification Setting and Benzodiazepine Polydrug Abuse. Journal of Psychoactive Drugs, Volume 24(2), pp. 145-156, 1990.

269.Seymour RB & Smith DE. Identifying and Responding to Drug Abuse in the Workplace: An Overview. Journal of Psychoactive Drugs, Volume 22(4), 1990.

270.Smith DE & Seymour RB. Psychoactive Substance Use Disorders. Continuum Encyclopedia of Counseling, Continuum Publishing Group, New York, 1991.

271. Smith DE & Seymour RB. Benzodiazepines. Comprehensive Handbook of Drug and Alcohol Addiction, Marcel Dekker, Inc., New York, 1991.

272.Seymour RB & Smith DE. Hallucinogens. Comprehensive Handbook of Drug and Alcohol Addiction, Marcel Dekker, Inc., New York, 1991.

273.Smith DE, Ehrlich P & Seymour RB. Current Trends in Adolescent Drug Use. Psychiatric Annals, Volume 21(2), 1991. 274. Landry MJ, Smith DE, McDuff D, et al. Anxiety and Substance Abuse Disorders: A Primer for Primary Care

Physicians. American Journal of Family Practice, Volume 4(1), pp. 447-456, July, 1991. 275. Landry M, Smith DE, McDuff D, ctal. Anxiety and Substance Abuse Disorders: The Treatment of High Risk Patients.

American Journal of Family Practice, Volume 4(1), pp. 447-456, July, 1991.


276.Smith DE & Seymour RB. Psychoactive Substance Use Disorders. Continuum Encyclopedia of Counseling. Continuum Publishing Group, New York, 1991.

277. Zweben JE, Smith DE & Stewart P. Psychotic Conditions and Substance Abuse Use: Prescribing Guidelines and Other Treatment Issues. Journal of Psychoactive Drugs, Volume 23(4), 1991.

278. Landry MJ, Smith DE & Steinberg JR. Anxiety, Depression and Substance Abuse Disorders: Diagnosis, Treatment and Prescribing Practices. Journal of Psychoactive Drugs, Volume 23(4), 1991.

279. Wesson DR, Smith DE & Seymour RB. Sedative-Hypnotics and Tricyclics. Substance Abuse: A Comprehensive Textbook. Williams and Wilkins, Baltimore, Maryland, 1991.

280Xandry MJ, Smith DE, McDuff DR & Baughman OL. Benzodiazepine Dependence and Withdrawal: Identification and Medical Management. Journal of Family Practice, Volume 5(2), 1992.

281.Smith DE, Lusher T & Seymour RB. Benzodiazepines and Other Sedative-Hypnotic Detoxification. Manual of the Detoxification of the Pregnant Addict. Department of Health Services, State of California, 1992.

282.Seymour RB, Smith DE & Ehrlich P. Counseling the Adolescent Drug Abuse Client. Plenum Publishing Corporation, New York, 1993.

283.SmithDE & Seymour RB. Drugs in the Workplace. Occupational Health and Safety, National Safety Council, Itasca, Illinois, 1992.

284.Seymour RB & Smith DE. Crack Cocaine: Prevention, Intervention & Spirituality. Treatment Centers Magazine, 1993.

285. Wesson DR, Smith D E & Seymour RB. Sedative Hypnotics and Tricyclics. Synopsis of Substance Abuse. Williams and Wilkins, Baltimore, 1993.

286. WessonDR, SmithDE & Seymour RB. Sedative-Hypnotics and Tricyclics. Clinical Handbook of Substance Abuse. Williams and Wilkins, Baltimore, 1993.

287.Smith DE, Buxton ME, Bilal R & Seymour RB. Cultural Points of Resistance to the Twelve Step Recovery Process. Journal of Psychoactive Drugs, 1993.

288. Wesson DR, Ling W & Smith DE. Prescription of Opioids for Treatment of Pain in Patients with Addictive Disease. Journal of Pain and Symptom Management, Volume 8(5), pp. 289-296, July, 1993.

289. Smith DE, Wesson DR & Ling W. Treatment of Multiple Drug/Alcohol Intoxication and Withdrawal. ASAM Principles of Addiction, ASAM, 1993.

290. Wesson DR, Smith DE& Washburn P. Medical Aspects of Chemical Dependency. Hazelden, 1993. 291.SeymourRB & SmithDE. The Psychedelic Resurgence. Hazelden, 1993. 292. Morrison MA, Smith DE, Wilford B, Ehrlich, P & Seymour RB. At War in the Fields of Play: Current Perspectives on

the Nature and Treatment of Adolescent Chemical Dependency. Journal of Psychoactive Drugs, Volume 25(4), October-December, 1993.

293. Smith DE. Haight Ashbury Revisited. Proceedings of the Hallucinogens, LSD and Raves Symposium, National Press Club, November, 1993.

294. Wesson DR & Smith DE. Benzodiazepines and Other Sedative-Hypnotics. Textbook of Substance Abuse Treatment. The American Psychiatric Press, pp. 179-190,1994.

David E. Smith, M.D. Pago 25

295. Smith DE. A A Recovery and Spirituality: An Addiction Medicine Perspective; Response Paper. Journal of Substance Abuse Treatment, Volume 11(2), pp. 111-112, 1994.

296. Wesson DR, Ling W, Smith DE. Zolpidem: An Addiction Medicine Perspective. California Society of Addiction Medicine News, Spring, 1994.

297. Wesson DR, Smith DE & Ling W. Prescription Drug Abuse and Addiction. Hazelden Educational Materials, Center City, MN, 1994.

298.Smith DE & Seymour RB. LSD: History and Toxicity. Psychiatric Annals, Volume 24(3), pp. 145-147, March, 1994. 299. Smith DE & Wesson DR. Benzodiazepine and Other Sedative-Hypnotic Dependence. Treatment of Psychiatric

Disorders, Second Edition, American Psychiatric Press, Volume 1, pp. 673-683. 300. Smith DE, Wesson DR & Calhoun SR. Rohypnol: Quaalude of the Nineties? CSAMNews, Summer 1995, Volume 22,

No. 2. 301.Smith DE, Galloway GP, Frederick SL, Gonzales M, Stalcup SA & Staggers FE. Gammahydroxybutyrate: A

Neurotransmitter of Abuse? California Society of Addiction Medicine Newsletter, Summer 1996, Volume 23, Number 1. 302.Smith DE, Galloway GP, Wesson DR, Calhoun SR. Update on Rohypnol: Abuse Patterns in Texas. Vol. 23, #2,

California Society of Addiction Medicine Newsletter,.Fall 1996, Volume 23, Number 2. 303.Calhoun SR, Wesson DR, Galloway GP, Smith DE. Abuse of Flunitrezepam (Rohypnol) and other Benzodiazepines in

Austin and Southeast Texas. Journal of Psychoactive Drugs, April-June 1996, Volume 28, Number 2, pp. 183-189. 304.Smith DE, Galloway GP, Newmeyer J, Knapp T, Stalcup SA. A Controlled Trial of Imipramine for the Treatment of

Methamphetamine Dependence. Accepted pending revisions, Journal of Substance Abuse Treatment. 305.Smith DE, Galloway GP, Frederick SL, Staggers FE, GonzalezM, Stalcup SA. Gammahydroxybutyrate: An Emerging

Drug of Abuse that Causes Physical Dependence. Addiction. 92(1), 89-96, 1997 306. Smith DE, Galloway GP, Seymour RB. Methamphetamine: An Old Problem Returns. American Society of Addiction

Medicine News. 11(1): 6-7, 1996. 307.Smith DE, Frederick SL, Galloway GP, Staggers FE, Stalcup SA. Gammahydroxybutyrate: A Putative

Neurotransmitter That is Abused and Causes Physical Dependence, in Harris, LS (ed): Problems of Drug Dependence, 1994: Proceedings of the 56th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc. Rockville, MD. National Institute on Drug Abuse, 1996.

308.Smith DE, Miller NS & Gold MS. Manual of Therapeutics for Addictions. John Wiley & Sons, Inc. 1997. 309.SmithDE. The 1995 Distinguished Lecturer in Substance Abuse. Journal of Substance Abuse Treatment. Vol 13(4), pp.

289-294, 1996. 310.SmithDE& Seymour, RB. Benzodiazepine: Disintossicazione. Medicine delle Tossicodipendenze (Italian Journal of the

Addictions). Vol. 5, 1-2,1997 311.Smith DE, Galloway GP, Newmeyer J, Knapp T, Stalcup SA. A Controlled Trial of Imipramine for the Treatment of

Methamphetamine Dependence. Journal of Substance Abuse Treatment, Vol. 13, pp. 493-497, November, 1996. 312.Smith DE & Miller NS. The Integration of Pharmacotherapy and Nonpharmacotherapy. Journal of Addiction

Diseases. Volume 16, pp. 51-64, Number 4,1997.

David E. Smith, M.D. Pago 26

313.SmithDE & Seymour RB. Addiction Medicine and the Free Clinic Movement. Journal of Psychoactive Drugs. Volume 29, pp. 155-160, April-June, 1997.

314. Smith DE & Seymour RB. The Many Meanings of Free. Humanism in the Health Sciences. Volume 2, pp. 6-7, Fall, 1997.

315. Smith, DE& Seymour RB. Ask Dr. Dave. New Times. Volume 4(6), November-December, 1997. 316. Seymour, RB, SmithDE. Treatment of Protracted Drug-Induced Syndromes. In Norman S. Miller, MD, ed. The

Principles and Practice of Addictions in Psychiatry. W.B. Saunders Company, Philadelphia, 1997. 317. Smith, DE & Seymour, RB. Cannabis and Cannabis Withdrawal. Journal of Substance Misuse, 2(1), 1997. 318.Smith, DE, Galloway, GP & Seymour, RB. Methamphetamine Abuse and Treatment. Valparaiso University Law

Review, 1997. 319. Seymour, RB & Smith, DE. Benzodiazepine Use and Misuse. Medicina delle Tossicodipendenze (The Italian Drug Abuse

Journal), 1997. 320.Smith, DE & Seymour, RB. Advances in Anticraving Agents: Adjunctive Use of Medication Continues as Relapse

Prevention Strategy. Employee Assistance, 8(4), 1996

321.Smith, DE & Seymour RB. Ask Dr. Dave. New Times. Volume 5(1), January-February, 1998. 322.Smith,DE& Seymour, RB. International Addictions Update. Journal of Psychoactive Drugs. Volume 30(1), pp. 111-

117, January-March, 1998. 323. Smith, DE & Seymour RB. Ask Dr. Dave. New Times. Volume 5(2), March-April, 1998, p. 7. 324.Smith, DE & Seymour RB. Ask Dr. Dave. New Times. Volume 5(3), May-June, 1998, p. 7. 325. Smith, DE. Review of the AMA Council on Scientific Affairs Report on Medical Marijuana. Journal of Psychoactive

Drugs. Volume 30(2), pp. 127-136, April-June, 1998. 326. Calhoun, SR, Galloway, G & Smith, DE. Abuse Potential of Dronabinol (Marino!®). Journal of Psychoactive Drugs.

Volume 30(2), pp. 187-196, April-June, 1998. 327. Smith, DE, Ehrlich, P & Seymour, R. Current Trends in Adolescent Drug Use. San Francisco Medicine. Volume 71(5),

pp. 22-23, 26, June, 1998. 328.Smith, DE & Seymour RB. Ask Dr. Dave. New Times. Volume 5(4), July-August, 1998, p. 7. 329.Smith, DE & Seymour RB. Ask Dr. Dave. New Times. Volume 5(5), September-October, 1998, p.7. 330.Smith, DE, LawlorB, & Seymour, RB. Health Care at the Crossroads. San Francisco Medicine, 69(6), 1996. 331. Seymour, RB, Smith DE. Cannabis Addiction and Withdrawal: Attitudes and Implications. In David T. Brown, ed.

Cannabis, The Genus Cannabis, OPA (Overseas Publishers Association), Harwood Academic Publishers, Amsterdam, 1998. 332.Smith, DE & Seymour RB. Ask Dr. Dave. New Times. Volume 5(6), November-December, 1998, p. 7. 333.Wesson, D, Smith, DE, Ling, W. Pharmacologic Therapies for Benzodiazepine and other sedative-hypnotic addiction.

Principles of Addiction Medicine, second ed. 517-530, 1998.


334.Smith DE & Wesson DR. Benzodiazepine and Other Sedative-Hypnotic Dependence. Textbook of Substance Abuse Treatment, Second Edition. Galanter, M & Kleber, HD, eds., American Psychiatric Press, pp. 239-250, 1999.

335.Seymour, RB & Smith, DE. Psychological and Psychiatric Consequences of Hallucinogens. Handbook of Substance Abuse: Neurobehavioral Pharmacology. RE Tarter, RT Ammerman & PJ Ott, eds., pp. 241-251, Plenum Press, 1998.

336.Smith, DE & Seymour, RB. Overcoming Cultural Points of Resistance to Spirituality in the Practice of Addiction Medicine. Addiction and Spirituality: A multidsciplinary Approach. Morgan, OJ, & Jornan, M., eds., pp. 95-109, Chalice Press, 1999.

337.Smifh, DE & Seymour RB. Ask Dr. Dave. New Times. Volume 6(1), January-February, 1999, p.7. 338.Smith, DE & Seymour RB. Ask Dr. Dave. New Times. Volume 6(2), March-April, 1999, p. 7. 339.Smith, DE & Seymour RB. Ask Dr. Dave. New Times. Volume 6(3), May-June 1999, p. 7. 340.Smith, DE & Seymour RB. Ask Dr. Dave. New Times. Volume 6(4), July-August, 1999, p. 7. 341.Smith, DE & Seymour RB. Ask Dr. Dave. New Times. Volume 6(5), September-October, 1999, p.7. 342.Smith, D & Heilig, S. "Medicalizing" American Drug Policy—A Much-Needed Focus on Prevention & Treatment.

San Francisco Medicine, Volume 72 (10), pp. 28-30, November/December, 1999. 343. Smith, DE, Glatt, W, Tucker, DE, Deutsch, R, Seymour, R. Drug Testing in the Workplace: Integrating Medical

Review Officer Duties into Occupational Medicine. Occupational Medicine: State of the Art Reviews, Volume 17(1), pp. 79-90, January-March 2002.

344. Ling, W & Smith, DE. Buprenorphine: blending practice and research. Journal of Substance Abuse Treatment, Volume 23(2002), pp. 87-92.

345. Ling, W, Wesson, DR, Smith, DE. Prescription Opiate Abuse. In: Substance Abuse: A Comprehensive Textbook, Lowinson, JH, Ruiz, P, Millman, RB, Langrod, JG, eds. pp. 459-468, Lippincott, Williams & Wilkins, 2005.

346. Wesson, DR, Smith, DE, Ling, W, Seymour, RB. Sedative-Hypnotics. In: Substance Abuse: A Comprehensive Textbook, Lowinson, JH, Ruiz, P, Millman, RB, Langrod, JG, eds. pp. 302-313, Lippincott, Williams & Wilkins, 2005.

347. WiIford, B, Smith, DE, Bucher, R. Prescription Stimulant Sales on the Internet. Psychiatric Annals, Volume 35 (3), pp. 241-252, March, 2005.

348. Coleman, JJ, Bensinger, PB, Gold, MS, Smith, DE, Bianchi, RP, DuPont, RL. Can Drug Design Inhibit Abuse? Journal of Psychoactive Drugs, Volume 37 (4). pp. 343- 362, December, 2005.

349. Smith, DE. An Upper/Downer Perfect Storm: The Coming World-Wide Drug Epidemic. Journal of Psychoactive Drugs, Volume 38 (4). pp. 535-536, December, 2006.

350. Wesson, DR, Smith, DE, Ling, W, Sabnani, S. Substance abuse: sedative, hypnotic, or anxiolytic use disorders. In: Tashman, A, Kay, JA, Lieberman, J, First, MB, Maj, M, eds. Psychiatry. Vol 1. Third ed. Chichester, England: John Wiley & Sons; 2008. pp. 1187-1200.

351. Smith, D, Raswyck, G. Rock Medicine: Extreme Medicine at San Francisco Bay Area Rock Concerts. San Francisco Medicine, Volume 82 (2). pp. 25-26, March 2009.

352. Smith, DE. Addictive Disease in Adolescence: A 40-Year Addiction Perspective. Counselor, The Magazine for Addiction Professionals. Volume 10 (3). pp. 42-46, June 2009.

1 -J>


353. Smith, DE. The Evolution of Addiction Medicine and Its San Francisco Roots. CSAMNews, Volume 36 (3). pp. 4-6, Winter 2009.

XV. Journal Theme Editor 1. Smith DE, Editor. Psychedelic Drugs and The Law. Proceedings, Volume 1(1), 1967. 2. Smith DE, Editor. Psychedelic Drugs and Religion. Journal of Psychedelic Drugs, Volume 1(2), 1967. 3. Smith DE, Editor. Current Marijuana Issues. Journal of Psychedelic Drugs, Volume 2(2), 1969. 4. Smith DE, Editor. Amphetamine Abuse Journal of Psychedelic Drugs, Volume 2(2), 1969. 5. Smith, DE, Editor. LSD: The Psychedelic Experience and Beyond. Journal of Psychedelic Drugs, Volume 3(1), 1970. 6. SmithDE & Gay GR, Editors. The Contemporary Heroin Scene, Part I: The Problem. Journal of Psychedelic Drugs,

Volume 4(2), 1971. 7. Smith DE, Editor. The Contemporary Heroin Scene, Part II: Treatment. Journal of Psychedelic Drugs, Volume 4(2),

1972. 8. Smith DE, Editor. Drug Abuse 1972. Journal of Psychedelic Drugs, Volume 5(1), 1973. 9. Smith DE & Wesson DR, Editors. The Politics of Uppers and Downers. Journal of Psychedelic Drugs, Volume 5(2),

1973. 10. Smith DE & Wesson DR, Editors. Drug Abuse 1973. Journal of Psychedelic Drugs, Volume 6(1), 1974. 11. Smith DE & Wesson DR, Editors. Community Approaches to Drug Treatment and Rehabilitation. Journal of

Psychedelic Drugs, Volume 6(2), 1974. 12. Smith DE & Wesson DR, Editors. Polydrug Abuse. Journal of Psychedelic Drugs, Volume 8(2) 1975. 13. Smith DE, Wesson DR & Bourne P, Editors. Innovative Approaches to Drug Abuse Treatment. Journal of Psychedelic

Drugs, Volume 8(3), 1976. 14. Smith DE, Editor. Drugs, History and Culture. Journal of Psychedelic Drugs, Volume 9(3), 1977. 15. Smith DE, Editor. Stimulant Use, Misuse: A Ten Year Follow Up. Journal of Psychedelic Drugs, Volume 10(4), 1978. 16. Smith DE, Editor. PCP: Problems and Prevention. Selected Proceedings of the National PCP Conference, Journal of

Psychedelic Drugs, Volume 12(3-4), 1980. 17. Smith DE, Editor. Sexological Aspects of Substance Use and Abuse. Proceedings, Volume 14(1-2), 1982. 18. SmithDE & WessonDR, Editors. The Benzodiazepines: Two Decades of Research and Clinical Experience.

Proceedings, Volume 15(1-2), January-June, 1983. 19. Smith DE & Wesson DR, Editors, Treating the Cocaine Abuser. Hazelden Foundation, 1985. 20. Smith DE & Wesson DR, Editors. MDMA: Ecstasy as an Adjunct to Psychotherapy and a Street Drug of Abuse.

California Society for the Treatment of Alcoholism and Drug Dependence News, September, 1985, 21. Smith DE & Wesson DR, Editors. The Benzodiazepines: Current Standards for Medical Practice. MTP Press, London. 22. Smith DE, Buxton ME & Zweben, JE, Editors. Professional Treatment and the 12 Step Process. Journal of Psychoactive

Drugs, Volume 19(3), 1987. 23. Seymour RB, Wesson DR & Smith DE, Editors. MDMA: Proceedings of the Conference. Journal of Psychoactive

Drugs, Volume 18(4), 1986. 24. Landry MJ, Smith DE & Newmeyer JA, Editors. AIDS and Chemical Dependency: Social and Clinical Issues. Journal

of Psychoactive Drugs, Volume 20(2), 1988. 25. Smith DE, Editor. Therapeutic Drugs and Drugs of Abuse in the Era of the Drug Free Workplace. Journal of

Psychoactive Drugs, Volume 22(4), 1990. 26. Smith DE, Editor. Prescription Drug Issues: Public Policy and Clinical Practice. Journal of Psychoactive Drugs,

Volume 23(4), 1991. 27. Dupont, RL, Smith, DE, Deutsch, R, Clark, HW, Editors. Drugs, Crime & Violence. Journal of Psychoactive Drugs,

Volume 29(4), 1997. 28. Smith DE & Heilig, S, Editors. Marijuana at The Millenium: Medical and Social Implications. Journal of Psychoactive

Drags, Volume 30(2), 1998.


XVI. Monographs 1. Smith DE, Contributing Author. Medical Care at Large Youth Gatherings. National Clearinghouse on Drug

Information, 1976. 2. Smith DE, Co-Author. Medical Treatment for Complications of Polydrug Abuse. Treatment Manual I, National Institute

on Drug Abuse, 1976. 3. SmithDE, Co-Author. The Diagnosis and Treatment of the PCP Abuse Syndrome. PCP Phencyclidine Abuse: An

Appraisal, Petersen & Stillman, August, 1978. 4. Smith DE, Co-Author. Cocaine: A Second Look. American Council on Marijuana and Other Psychoactive Drugs,

Rockville, Maryland, 1983. 5. Smith DE & Wesson DR. Cocaine: Treatment Perspectives. Cocaine Use in America: Epidemiological and Clinical

Perspectives, Institute on Drug Abuse Research Monograph Series 61, 1985. 6. Smith DE, Wesson DR, Steffens S & Jue K. L-Tryptophan Treatment of Cocaine Dependency and the Eosinophilia

Myalgia Syndrome. Problems of Drug Dependence, NIDA Research Monograph #132, Rockville, Maryland, 1992.

XVIII. Published Abstracts: 1. Schermann, JM, Sandouk, P, Redureau, M, Galons, H, Hiance, M, Kaplan, SA, Smith, DE. Inhibition of cocaine brain

uptake and facilitation of cocaine efflux from the brain by a systemic specific antibody. Published abstract. College on Problems of Drug Dependence (CPDD), 61 a Annual Scientific Meeting, June 1 2 - 1 7 , 1 9 9 9 , Acapulco, Mexico.

2. Kaplan, SA, Smith, DE, Markland, P, Perkins, BH, Ferrell, TM, Fulton, R, Nettles, HS, Staas, JK, Tice, TR. In vivo confirmation of naltrexone sustained release by microencapsulation In poIy(D,L-lactide) for prolonged drug addiction therapy. Published abstract. College on Problems of Drug Dependence (CPDD), 61st Annual Scientific Meeting, June 12 -17,1999, Acapulco, Mexico.

XVII. Books 1. Smith DE, Co-Editor. Drug Abuse Papers 1969. University of California, Berkeley, 1969. 2. SmithDE, Editor. The New Social Drug: Cultural, Medical and Legal Perspectives on Marijuana. Prentice-Hall, Inc,

1970. 3. Smith DE, Co-Author. Love Needs Care: A History of San Francisco's Haight Ashbury Free Medical Clinic. Little Brown

& Co., 1971. 4. Smith DE, Co-Editor. The Free Clinic: Community Approaches to Health Care and Drug Abuse. STASH Press, 1972. 5. Smith DE, Co-Editor. It's So Good, Don't Even Try It Once: Heroin in Perspective. Prentice-Hall, Inc., 1972. 6. Smith DE, Co-Author. Drugs in the Classroom. The C.V. Mosby Co., 1973. 7. Smith DE, Co-Editor. Uppers and Downers. Prentice-Hall, Inc., 1973. 8. Smith DE, Co-Author. Barbiturates: Their Use, Misuse and Abuse. Behavioral Publications, Inc., 1976. 9. SmithDE, Co-Editor. A Multicultural View of Drug Abuse: Proceedings of the National Drug Abuse Conference 1977.

Schenkman and G.K. Hall Publishers, Cambridge, Massachusetts, 1978. 10. Smith DE, Co-Editor. Amphetamine Use, Misuse and Abuse: Proceedings of the National Amphetamine Conference 1978.

G.K. Hall Publishers, Boston, 1979. 11. Smith DE, Wesson DR & Eiswirth NA. Cocaine in America. Hazelden Foundation, Minneapolis, 1981. 12. Smith DE, Co-Editor. PCP: Problems and Prevention. Kendall Hunt, Dubuque, Iowa, 1982. 13. Smith DE, Medical Consultant. The Little Black Pill Book. Bantam Books, New York, 1983. 14. Smith DE, Medical Consultant. The Coke Book. Berkeley Books, New York, 1984. 15. Smith DE, Gold MS, Olden K & Dwyer B J. Cocaine: Helping Patients Avoid the End of the Line. 1985. 16. Smith DE & Wesson DR. Treating the Cocaine Abuser. Hazelden Foundation, 1985. 17. Smith DE, Co-Editor. The Benzodiazepines: Current Standards for Medical Practice. MTP Press, Ltd., Boston, 1985. 18. Seymour RB & Smith DE. The Physician's Guide to Psychoactive Drugs. The Haworth Press, New York, 1987. 19. Seymour RB & Smith DE. Guide to Psychoactive Drugs: An Up to the Minute Reference to Mind Altering Substances.

Harrington Park Press, New York, 1987.


20. Seymour RB & Smith DE. Drugfree: A Unique, Positive Approach to Staying off Alcohol and Other Drugs. Facts on File Publications, New York, 1987.

21. Seymour RB & Smith DE. Still Free After All These Years: Two Decades With The Haight Ashbury Free Medical Clinic. Westwind Associates, Sausalito, 1987.

22. Smith DE & Wesson DR. Treating Cocaine Dependency. Hazelden Foundation, Minneapolis, 1988. 23. Wesson D R & SmithDE. Treating Opiate Dependency. Hazelden Foundation, Minneapolis, 1989. 24. Seymour RB, Smith DE, Inaba DE & Landry MJ. The New Drugs: Look Alike Drugs, Drugs of Deception and Designer

Drugs. Hazelden Foundation, Center City, 1989. 25. Wesson DR, Smith DE, Steffens SC, Co-Editors. Crack and Ice: Treating Smokable Stimulant Abuse. Hazelden

Foundation, Center City, 1992. 26. Smith, DE & Seymour, RB. Clinician's Guide to Substance Abuse. McGraw-Hill Medical Publishing Division, 2001.

XVIII. Drug Abuse Films, Consultant 1. LSD-25,1967. 2. Guidance Associate Film Series, 1968. 3. You Can't Grow a Green Plant in a Closet, 1968. 4. The Speed Scene, 1969. 5. Darkness, Darkness, 1970. 6. Glass House, 1971. 7. Junkies Are People, 1973. 8. Film on the National Commission on Marijuana and Drug Abuse Report, 1973. 9. Escape to Nowhere, 1978. 10. Uppers, Downers, All Arounders. Cinemed Inc., 1984; CNS Productions, Inc., 2001. 11. Through the Looking Glass. Hazelden, 1984. 12. The Haight Ashbury Cocaine Film. Cinemed, Inc., 1985. 13. Haight Ashbury Video Series. Cinemed, Inc., 1988. 14. Haight Ashbury Heroin Film, 1999.

###

This affidavit is based upon my personal knowledge and upon my review of the

materials identified hereinabove. It is not the purpose of this affidavit to set forth each

and every criticism I have or may have in the future based upon further review and

consideration of information concerning the care and treatment of Patrick W. Desmond.

I have expressed my opinions to a reasonable degree of medical certainty. I understand

that this affidavit will or may be used in connection with the prosecution of a lawsuit,

and for any other purpose allowed by Georgia law.

FURTHER AFFIANT SAYETH NOT.

DAVID E. SMITH, M.D. Sworn to and subscribed

day of K< 2010.

NOTARY PUBLIC My commission expires: j2A i

SIM. of Olffonrt., County of L Rfl, | ^(

Subscribe »nd sworn to (or «ffirm«d) before n

SlflnMurt:

7